CA2063886C - Polyethylene protein conjugates - Google Patents

Polyethylene protein conjugates Download PDF

Info

Publication number
CA2063886C
CA2063886C CA002063886A CA2063886A CA2063886C CA 2063886 C CA2063886 C CA 2063886C CA 002063886 A CA002063886 A CA 002063886A CA 2063886 A CA2063886 A CA 2063886A CA 2063886 C CA2063886 C CA 2063886C
Authority
CA
Canada
Prior art keywords
protein
alpha
conjugate
lra
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002063886A
Other languages
French (fr)
Other versions
CA2063886A1 (en
Inventor
John Hakimi
Patricia Kilian
Perry Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27101069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2063886(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2063886A1 publication Critical patent/CA2063886A1/en
Application granted granted Critical
Publication of CA2063886C publication Critical patent/CA2063886C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Abstract

The present invention relates to physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugates having at least part of the biological activity of the protein which forms the conjugate, without exhibiting the same disadvantageous immunogenic responses thereof.

Description

The present invention relates to novel polyethylene glycol (PEG) conjugates of proteins.
Various natural and recombinant proteins have medical and pharmaceutical utility. Once they have been purified, separated, and formulated, they can be parenterally administered for various therapeutic indications. However, parenterally administered proteins may be immunogenic, may be relatively water insoluble, and may have a short pharmacological half life. Consequently, it can be difficult to achieve therapeutically useful blood ' levels of the proteins in patients.
These problems may be overcome by conjugating the proteins to polymers such as polyethylene glycol. Davis et al., U.S. Pat. No.
4,179,337 disclose conjugating polyethylene glycol (PEG) to proteins such as enzymes and insulin in order to result in conjugates where the protein would be less immunogenic and would retain a substantial proportion of its physiological activity. Nakagawa, et al., U.S. Pat. No.
4,791,192 disclose conjugating PEG to islet-activating protein to reduce its side-effects and immunogenicity. Veronese et al., Applied Biochem. and Biotech, 11:141-152 (1985) disclose activating polyethylene glycols with phenyl chloroformates to modify a ribonuclease and a superoxide dimutase. Katre et al. U.S. Pat. Nos.
4,766,106 and 4,917,888 also disclose solubilizing proteins by polymer conjugation. PEG and other polymers are conjugated to recombinant proteins to reduce immunogenicity and increase half-life.
See Nitecki, et al., U.S. Pat. No. 4,902,502, Enzon, Inc., International Application No. PCT/LTS90/02133, Nishimura et al., European Patent Application 154,316 and Tomasi, International Application Number PCT/US85/02572. King et al., Int. Archs. Allergy appl. Immun. 6~, 439-446 (1981) describes a method for linking proteins to PEG by Lo/10.2.92 _2_ using O-(RO-PEG)-S-carboxamidomethyl-dithiocarbonate intermediates.
Previous methods of forming PEG-protein conjugates and the conjugates which result from said methods present several problems.
Among these problems is that certain methods of forming these protein-PEG conjugates may inactivate the protein so that the resulting conjugates may have poor biological activity. In addition, certain linkers utilized in forming these PEG-protein conjugates may be susceptible to in vivo hydrolytic cleavage. When such cleavage occurs after administration, these conjugates lose the beneficial properties provided by PEG.
The present invention provides novel PEG-protein conjugates through the use of unique linkers which connect the various free amino groups in a protein to PEG which circumvent the problems associated in the formation of conjugates of a protein with PEG.
In particular the present invention provides a physiologically active conjugate of a protein of the formula Rl-O-(CHzCH20~-CH2CH2-Rz~ ~ H Protein C
II
R3 m J
wherein R1 is lower alkyl; R2 is -O- or -NH-; R3 is =N-Rq., =S or =O; R4 is lower alkyl or cycloalkyl; m and n are selected from integers >_ 1 in a way that the conjugate has at least a portion of the ' biological activity of the non conjugated protein;
with the proviso that when R2 is -O-, R3 is other than =N-R4;
that when R2 is -O- and R3 is =O the protein is interferon-alpha, interleukin-1 or interleukin-lra and that when R2 is -O- and R3 is =S

the protein is not antigen E from ragweed pollen or bovine plasma albumin.
One embodiment of the present invention is a physiologically active conjugate of a protein of the formula NH protein R~ fl-(CH2CH20~-CH2CH2-R~~ ~
C
R3 m wherein R1 is lower alkyl; RZ is -0- or -NH-; R3 is =N-R4, =S or =O; R4 is lower alkyl or cycloalkyl wherein alkyl contains 1 to 6 carbon atoms; m and n are selected from integers z 1 in a way that the conjugate has at least a portion of the biological activity of the non conjugated protein; and wherein the protein is interleukin-l, interleukin-lra, interferon-alpha or interleukin-2, , with the proviso that when RZ is -O-, R3 is other than N-R4; and that when RZ is -O- and R' is +O the protein is not interleukin-2.
More specifically, the present invention provides protein conjugates of the formulas:
H H
N N protein I~A
R1-0(CHzCHzOIn-CHzCHz~
NR4 m H
~-0(CHZCH20n-CHZCHZ-0 N P~tein I~B
m H
N NH protein R~-0(CHZCHZO~-CH2CH~ 'C~ I-C
. a N
H NH protein R1-0-(CHzCH20)~ HzCH2~ 'C/ I~D
~ m - /0~ ~N . protein R~-0-(CH2CH20) p H2CH2 C I-E
0~ m wherein Rl, R4, m , n and the protein are as above.

2~~~8~~

In accordance with the present invention, we have also provided for the first time the protein interleukin-1 receptor antagonist (IL-lra) and interleukin-1 (IL-1) conjugated to PEG.
In accordance with this invention, the conjugate of a protein of formula I is produced by condensing activated PEG, viz. PEG wherein one hydroxy group has been replaced by an activated linker, with one or more of the free amino groups in the protein. The activated PEG
compounds used to produce the conjugate have the following formulas:
II-~-1 Rl~(~2~2p)n ~2~2 N-L'' ~N~R,4 v II-~ Rl O(CH2CHZO~ C~I2CH~-- ~ - C °
S
RS
v l ~I-C R1O CI-I CH O - C~H CH -NH - C °-O -'~
( 2 2 )n 2 2 II N

;I'~ R10W2~a0)ri ~a'~i N =C =S
v~
II-E R1 O(CH2CFi20)ri CH2CH2-NH - C ° O - ~~
~I RS
S
1(I-F R10(CH2CH2O)ri CH2CH2-O - C --O
S
O
v~
IT-('x R10(CH2CH20)n CH2CH2--~~C-O-- ~ s~
N

2063~~6 -s-wherein R1 is lower alkyl, R4 is lower alkyl or cycloalkyl, and R~ is lower alkyl or I~ and n is an integer of from 1 to 1000.
In accordance with this invention, by using the activated PEG
compound of formula II-A, II-E, II-C, II-D, II-E, II-F or II-G to produce the conjugates, a linking bond _between the free amino groups in the protein and the PEG is formed so that the resulting conjugate retains at least a portion of the biological activity of the protein while reducing its immunogenicity. In addition, the linkage groups formed in the conjugate of this invention through the use of any one of the activated polyethylene glycols of formulae II-A through II-G
produces a protein conjugate which is not readily susceptible to in vivo hydrolytic cleavage and is not subject to many of the disadvantages present in the PEG protein conjugates of the prior art.
In accordance with this invention, Rland R$ can be any lower alkyl, preferably methyl. The term lower alkyl designates lower alkyl groups containing from 1 through 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, etc. Generally the preferred alkyl group is a lower alkyl group containing from 1 to 4 carbon atoms with methyl being most preferable.
In accordance with this invention, m and n can be selected from any integer >_ 1 in a way such that the resulting conjugate of a protein has at least a portion of the biological activity of the protein which forms the conjugate. It is apparent that the sum of n and m is inversely proportional to the amount of biological activity of the protein which is retained by the conjugate. The numerical value of n relates the number of ethylene glycol units in the polyethylene glycol 3o which form the conjugate and is between 1 and 1000. The term m relates to the number of free amino groups contained by the protein which is reacted with the activated PEG. Preferably the value of m is in the range of 1 to 5 with 1 being the most preferred one. The higher the value of m + n, the higher is the molecular weight of the wo~~~~~
conjugate. The molecular weights of the polyethylene glycol polymers of formulae II-A to II-G and of the protein conjugates of formulae I
and I-R to I-E can be easily determined by a person skilled in the art.
From the molecular weights determined the values of m and n can be deduced. The term protein comprises on the one hand polypeptides and on the other hand physiologically acceptable addition salts.
When the compound of any one of formula II-A through II-G is reacted with the protein and the protein contains more than one free l0 amino group, the conjugate may be produced as a mixture of various protein PEG conjugates. In cases where the protein contains two free amino groups, the activated PEG can react both with one of the free amino groups and with both of the free amino groups. In this situation the mixture contains one conjugate formed where two free amino groups are reacted with PEG and a second conjugate formed where only one free amino group is reacted with PEG. Since the various conjugates in this mixture have different molecular weights, these conjugates can be separated by conventional methods such as chromatography. To determine if m and n have been selected 2o properly, the separated conjugates can be screened for biological activity by the same means used to screen the parent protein to determine if the conjugate still retains a portion of the biological activity of the protein used to form the conjugate. In this manner, the numbers m and n can be adjusted in any desired manner to provide the desired activity.
In accordance with the preferred embodiment of this invention m and n are any integer so that molecular weight of the conjugate, excluding the weight of the protein, is between approximately 300 to 3o approximately 30,000 daltons. In accordance with the preferred embodiment, m is 1. Where m is 1, this conjugate can be obtained even when there are two or more free amino groups. The activated PEG compound will react first with one of the free amino groups contained within the protein groups. By regulating the concentration 2~63~~~
of the reagents such as the protein, and reaction conditions, in accordance with standard methods of amine condensation, one can regulate the degree of pegylation of the free amino groups contained within the protein. In proteins containing one or more free amino groups, where one of the free amino groups is more reactive than the other amino groups, conditions may be selected so that the protein is reacted with the activated PEG compound to form the compound of formula I where m is 1. Other free amino groups contained within amino acids which form the protein may be subsequently reacted 1 o with the PEG by allowing the condensation reaction to proceed longer or by utilizing other stronger conditions. In accordance with a preferred embodiment where m is 1, n is any integer so that the polyethylene glycol which forms the conjugate has a molecular weight of from 300 to 30,000 daltons corresponding to n in being approximately 6 to 680. More preferably n is about 28, 112 and 225 corresponding to molecular weights of 1325, 5000 and 10000 respectively, with n being in the region of 112 as the most preferred one. Characterizing the polyethylene glycol polymer by molecular weight is preferred over designating the self repeating units in the PEG polymer with the integer n due to the potential ~ inhomogeneity of the starting PEG compounds which are usually defined by their avarage molecular weight and not their self-repeating units. The starting PEG compounds of various molecular weights can be prepared by methods known in the art or can be obtained from commercial suppliers.
in case the values of m and n obtained by determination of the molecular weights are not integers (as will generally be the case), there values have to be rounded up or off in the usual way.
Where R4 is lower alkyl, R4 can be any lower alkyl group containing from 1 to 6 carbon atoms such as defined above. When R5 is cycloalkyl, RS is preferably a eycloalkyl group containing from 3 to 2~~3~~~
_g_ 7 carbon atoms such as cyclopropyl, cyclopentyl, cyclobutyl, and cyclohexyl. The preferred cycloalkyl group is cyclohexyl.
The title compounds of each of the following .Examples are named in accordance with IUPAC nomenclature. However, these compounds may also be named as follows:
Examples 1, 2, 3, and 4:
to Alpha-[2-[[cyclohexylcarbonimidoyl)-amino]ethyl]-omega-methoxypoly(oxy-1,2-ethanediyl) is alternatively _ named alpha-[2-[ [(cyclohexylamino)methylene]amino]ethyl]omega-methoxypoly-(oxy-1,2-ethanediyl).
Examples 1A, la, and 1d:
Alpha-(2-chloroethyl)-omega-methoxypoly(oxy 1,2-ethanediyl) is alternatively named alpha-methoxy-omega-(2-chloroethyl)poly(oxy-1,2-ethanediyl).
Examples 1 B, 1 b, and 1 e:
Alpha-(2-azidoethyl)-omega-methoxypol;y(oxy-1,2-ethanediyl) is alternatively named alpha-methoxy-omega-(2-azidoethyl)poiy(oxy-1,2-ethanediyl).
Examples 1C, lc, and 1f:
Alpha-(2-aminoethyl)-omega-methoxypoly(oxy-1,2-ethanediyl) is 3o alternatively named alpha-methoxy-omega-(2-aminoethyl)poly(oxy-1,2-ethanediyl).
Examples 11, 11a, Ilb, 12, 12A, and 13-17: Alpha-methyl-omega-[2-[[(2-pyridinyloxy)carbonyl]amino]ethoxy]poly(oxy-1,2-ethanediyl) is ~os~g~s alternatively named alpha-[2-[[(2-pyridinyloxy)carbonyl]amino]ethyl]-omega-methoxypoly(oxy-1,2-ethanediyl).
Examples 18, 18a, 19, 19A, 20, 20A, 21, and 22:
Alpha-((2-pyridinyloxy)carbonyl]omega-methoxypoly(oxy-1,2-ethanediyl) is alternatively named alpha-methyl-omega-(2-[[(2-pyridinyloxy)carbonyl]oxy]-ethoxy]poly-(oxy-1,2-ethanediyl).
Examples 23-27:
Alpha-(2-(isothiocyanato)ethyl]-omega-methoxypoly(oxy-1,2 ethanediyl) is alternatively named alpha-[methoxy-omega-[2 (isothiocyanato)ethyl]poly(oxy-1,2-ethanediyl).
Example 28:
Alpha-[(2-pyridinyloxy)thiocarbanyl]-onnega-methoxypoly(oxy-1,2-2o ethanediyl) is alternatively named alpha-methyl-omega-[2-[[(2-pyridinyloxy)thiocarbonyl]oxy]ethoxy]-poly(oxy-1,2-ethanediyl).
The present invention also comprise, the process for the preparation of the PEG-protein conjugates of the general formula I or formulae I-A through I-E which process comprises reacting one of the activated compounds of the general formulae ~a-.E~ Rl~(~2~-j2o~. ~2~2 ~ =C =
II-B R10(C~I2CI~2p~ CH2G~I2 II l S

- ~O~Jg~6 RS
m.c Rlo cH cH o - cal cH -rrH --~ c -~o ~ ~ 0 2 2 )n 2 2 ~I-I3 R1O(CHZCH2O)"CH2-CH2 N = c _-_S
II-E Rlo(CH2CH2o)ri CH2CH2-NiI --y C °-O - ~
i~ RS
S
II-16' Ri0(CH2CHZO)ri CH2CH2 0 ~ c -o eN ~
s II-G R10(CH2CH20)~CH2CH2-o-C-O- w s , whexein R1, RS and n are as defined above, with a free amino group of a protein or a salt thereof and isolating the protein conjugate from the reaction mixture.
t0 In particular, the synthesis of the individual PEG derivatives to be coupled with a protein as well as their reaction with the protein can be performed as described in the following paragraphs and in the Examples.

To produce the protein conjugate wherein R2 is -NH-; and R3 is =N-R4, (the compound of formula I-A) the following reaction scheme may be employed:

__.,, 2~~38~~

R1 O(CHZCH20)aC~IZCH2-OH SOX~~ R1 C(~Z~ZC)n~z~2X
NaN3, DMF
i R1 O(CHZCHaO)aCH2CH2NH2 ~ H~ R1 o(CH2CH20)aCH2CH2N3 R4-N=C=S
r H SH
R1O(CH2CH2O)aCH2CH2N~~.N°F~
H S~ H (CsHs) P, CC1, 1 R1O(CH'2CH2O)aCH2CH2N'~'N'F~ ~ ~-~- R O(C$2CH20)aCHZCI32N=C~N°R4 III
II A

H H
N N protein Ri-O(CH2CH20)ri CH,~CH2 ~ I-A
NR4 ~
wherein R1, R4, n, m and the protein are as above, In the reaction scheme, the hydroxyl group at the end of the PEG molecule is converted to a halogen group by conventional means such as by treatment with a thionyl halide. The resulting PEG halide 1 o is converted to an azide by conventional means such as by treatment with sodium azide. The PEG azide can then be converted to an amine by conventional means such as hydrogenation. The PEG-amine is then reacted with an alkyl or cycloalkyl isothiocyanate such as cyclo-hexylisothiocyanate to form the thiourea of formula III which is then desulfurized by conventional means to form the compound of formula II-A which contains the carbodiimide functional group. In converting the thiourea of formula III into the PEG carbodiimide of formula IIA, the preferred desulfurizing agent is triphenyiphosphine.
1 o The PEG carbodiimide of formula II-A can then be condensed with a protein under any conventional conditions for condensing carbodiimides with amines. Generally this reaction is carried out in a standard aqueous buffer solution having pH of between 7 and 9 to produce the conjugate of formula I-A. The resulting condensation reaction may produce a mixture of PEG protein conjugates of various molecular weights depending upon the number of free amino groups within the protein and the time of the reaction. The PEG protein conjugates may then be separated into their individual components by conventional methods such as high performance liquid 2o chromatography or gel electrophoresis.
To produce the protein conjugate where RZ is -O- and R3 is =S
(the compound of formula IB), the following reaction scheme can be employed.

R1O(CH~CH2O)nCH2CH2-OI-I -E \ J
N I
O S O
-n- R1O(CH2CI-I2O)nGI-I2CH2_~
O
II-B S
NH2-protein H
Rt-O(CH2CH20~-CH2CH2-O N protein a-1~
wherein R 1, m, n and the protein are as .above, In this reaction a PEG is refluxed with 1,1-carbonothioylbis-2(1H)-pyridinone in a high boiling hydrocarbon solvent to produce the compound of formula II-B. The compound of formula II-B can be condensed with one or more of the free amino groups of the protein to produce the conjugate of formula I-B in the same manner as described in connection with the condensation of the compound of formula II-t~ with a protein to prepare the conjugate mixture of formula I-t~. Separation of this mixture can be carried out according to molecular weights of the products formed as described hereinbefore.

Alternatively, the protein conjugate of the present invention where Rz is -O- and R3 is =S, (the compound of formula I-B) can be produced by the following reaction scheme:
/ ~ S
R1O(CH2CHaO)2CH2CH2OH +
O~O ~ N
~I
S
Rt0(CH CH O) CH CH O ~O
2 2 n 2 2 II-F
NH2-protein I-I
Rl-O(CH2CH20)n CH2CH2-O N protein I-B
m wherein R 1, m, n and the protein are as above.
In accordance with this scheme, PEG is reacted with the thiocarbonate of formula VI in an organic solvent to form the PEG
thiocarbonate of formula II-F. Any conventional method of condensing a thiocarbonate with a hydroxy group can be used in carrying out this reaction.
The compound of fornnula II-F is converted to the conjugate of formula I-B by condensing the compound of formula II-F with at least one free amino group of the protein. This reaction is carried out in 2a~38~~
-~s-the manner described for the conversion of compound of formula II-A to the conjugate of formula I-A. The product that is produced by this reaction can be a mixture of conjugates of different molecular weights depending upon the amount of free amino . groups in the protein used. These conjugates can be separated by molecular weight in accordance with the procedure hereinbefore. described.
To produce the protein conjugate wherein R2 is -NH- and R3 is =O (the compound of formula I-C), the following reaction scheme can be used:
~5 \ O
Cl-~-Cl N \0H
\~ O ~
N "O"O ~ N
IV
R10(CH2CH20)nCH2CH2NH2 O ~ /
R10(CH2CH20)ri CH2CH2- N ~~ ~N
H
II-C

2~63~~~
- l~ -NH2-protein H
N N protein Rt-O(CH2CH20)n CH2CH2 ~ t ~ I-C
O
wherein R1, R5, m, n and the protein are as above.
The compound of formula IV is produced by condensing phosgene with 2-hydroxypyridine (substituted if RS = lower alkyl) using any conventional method for condensing an acid halide with an alcohol.
The condensation of a PEG amine with the compound of formula IV is effected by refluxing in a halogenated hydrocarbon solvent to produce the compound of formula II-C. The compound of formula II-C is condensed with the protein through one or more free amino gxoups on the protein to produce the compound of formula I-C. This reaction is carried out in the manner described .for the condensation of the compound of formula II-A to produce the conjugate of formula I-A. Depending upon the number of free amino groups contained within the protein which react with the compound of formula II-C, the conjugate of formula I-C may be formed as a mixture of conjugates having different molecular weights. This conjugate mixture can be separated in the manner described hereinbefore.
To produce a protein conjugate of the present invention wherein R2 is -NH- and R3 is =S (the compound of formula I-D), the following reaction scheme can be used.

- l~ - 2~~~~~6 R10(CH2CH2O)nCH2CH2NH2 + Di-2-pyridyl thionocarbonate Ri0(CH2CH20)"CHaCH2N=C~S
II-D
NHS-protein N
H NH protein R10-(CH2CH20)"CH2CH2 ~~~ m S
I-I) wherein R1, m, n and the protein are as above.
In this reaction scheme:, PEG amine: is reacted with di-2-pyridylthionocarbonate to produce the coimpound of formula II-D. In this procedure any conventional method of condensing an amine with a thiocarbonate to produce an isothiocyanate can be used. The;
compound of formula II-D is reacted with the protein to form the 1 o conjugate of formula I-D in the manner described for the conversion of the compound of formula II-A to the compound of formula I-A.
Depending upon the amount of free amino groups contained by the:
protein, condensation of the compound of formula II-D with the:
protein produces a mixture of conjugates which can be separated into their individual components 'in the manner hereinbefore described for the separation of the conjugate of formula I.
Alternatively, the: compound of formula I-D can be produced using the following reaction scheme:

_ 18 _ / S
+ Cl-~-Cl R °' N OH
R N O~O N ~ RS
V
R10(CH2CH20)2CHZCHZNH2 R10(CH2CI320)"CH2CH2NH~p N RS
II-E
NH2-protein ~(-I?
The compound of formula V is produced by condensing thiophosgene with 2-hydroxypyridine (substituted where RS is lower alkyl), using any conventional method for condensing an acid halide with an alcohol. V is then reacted with a PEG-amine in the manner described for producing the compound of II-C. The resulting 1 o compound is II-E. The compound of formula II-E is condensed with one or more free amino groups on a protein to produce the conjugate 2D~~~~~

of formula I-D. This reaction is carried out in the manner described for the formation of conjugate I-A.
To produce a protein composition of the present invention wherein R2 is -O- and R3 is O (the compound of formula I-E), the following reaction scheme can be used.
r ( ~ r R10(CH2CH2O)zCH2CH20H + ~
°N O' °O °NJ
O
R10(CH CH O) CH CH O ~O °N~
2 2 n 2 2 II-G
NHf2-protein ~,0~ ~N protein Rl-O-(CH2CH20)n CH2taH2 C
O 'n to wherein R1, m, n and the protein are as above.
In the above reaction scheme di-2-pyridyl carbonate is reacted with PEG to produce the compound of formula II-G. This reaction is carried out by conditions conventional in condensing an alcohol with a carbonate. The compound of formula II-G is converted to the compound of formula I-E by condensing the compound of formula II-G with one or more free amino groups in the protein. This reaction is carried out in the same manner as described in connection with the conversion of the compound of formula II-A to the compound of formula I-~.. The reaction mixture thus produced can contain a mixture of the conjugated of formula I-E depending upon the free amino groups contained by the protein. This mixture constitutes a mixture of various conjugates of different molecular. weights. The various conjugates can be separated from the mixture in accordance with procedure described hereinbefore.
In accordance with a preferred embodiment of this invention, a conjugate of an interferon-alpha with PEG can be produced by the 0 following reaction scheme.
O ~
R10(CH2CH2O)"CH2CH2-N' °O ~N~
H
II-C
NI-I2-interferon-alpha r i-1 N NH-interferon-alpha Rl-O(CH2CH20)ri CH2CH r ~C'~
(I
O
wherein R1 is methyl, n is about 112. This reaction is of special interest for interferon-alpha of the subtyp interferon-alpha A (also named interferon-alpha 2).
The synthesis of the activated PEG compound II-C is described hereinbefore in connection with the synthesis of a protein conjugate wherein R2 is -NH- and R3 is =O. The final conjugate of interferon-alpha can be obtained in an analogous manner as described hereinbefore or in the Examples For the synthesis of the protein conjugate I-C.

~~~3886 Any protein with a physiological activity or a salt thereof may be used for the preparation of a conjugate with PEG provided that this protein contains at least one amino group for condensation.
Preferred proteins which can be used in the present invention are interleukin-1 (IL-1), interleukin-1 receptor antagonist (IL-lra), interleukin-2 (IL-2) and interferons, viz. IFN-alpha (leukocyte inter-ferons), IFN-beta (fibroblast interferon) and IFN-gamma (immune 1 o interferon), their naturally occurring forms as well as analogs, homologs or truncated forms thereof.
The interleukin-1 receptor antagonist (IL-lra) herein may be obtained from tissue cultures or by recombinant techniques. One ~5 method of obtaining Il-lra is to rest U937 human myelomonocytic cells (ATCC CRL 1594) with the differentiating agent phorbol myristate acetate (FMA) and then stimulate them with Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF; obtainable from Amgen), and isolating and purifying the itL-lra from the culture 20 supernatant liquid as described by Carter et al. Nature 44, 633-637 ( 1990).
Recombinant IL-lra refers to IL-lr~a having comparable biological activity to native IL-Ira but prepared by recombinant 25 techniques as described by Carter et al. supra or by Eisenberg et al.
Nature ~4 3 , 341-346 ( 1990).
Interferon includes all types of interferons, such as a, Vii, y or w interferons, and any subtypes of any types. Interferons may be 30 obtained from tissues or tissue cultures, or may be produced using recombinant techniques described in the literature, e.g. as described in European Patent Application, Publ. No. 43 980. Other methods for generating and isolating natural or recombinant interferons are also well known in the art.

~~~3~86 In accordance with this invention, it has been found that the protein-conjugates of this invention have the same utility as the protein used to form the conjugate. Therefore, these conjugates are therapeutically active in the same manner as the protein from which they are formed and can be used in the same manner as the. protein itself without producing the undesired immune responses which may be connected with the administration to subjects of the proteins themselves.
Therefore, the present invention also comprises the pharmaceutical 1 o compositions on the basis of the compounds of formula I or their salts and to methods for producing them.
The pharmaceutical compositions of the present invention used in the control or prevention of illnesses comprises a protein conjugate of the general formula I and a therapeutically inert, non toxic and therapeutically acceptable carrier material. The pharmaceutical compositions to be used can be formulated and dosed in a fashion consistent with good medical practice taking into consideration the disorder to be treated, the condition of the individual patient, the site of delivery of the protein conjugate, the method of administration and other factors known to practitioners.
The following examples represent illustrative embodiments of the present invention without limiting it by them.

Example 1 Preparation of aloha-f2-f~(~yclohexplcarbonimidovl)-aminolethvll-omega-methox~,polv(oxv-1.2 ethanedivll SR 1 111.7.
A. Preparation of alpha-(2-Chloroethyl)-omega-methoxYpoly 1.2-ethanedi~) SRU 111 7 (As used herein SRU designates the number of self-repeating units present in the PEG polymer).
From a slurry of SO g MPEG (methoxypolyethylene glycol, molecular weight-5000) in 700 ml of toluene was distilled 200m1 of the solvent. To the refluxing solution was added dropwise 0.8 ml of dry pyridine and 2.2 ml of thionyl chloride. After refluxing for four hours the reaction was allowed to stir overnight. The solvent was then removed under reduced pressure and SOOmI of CH2C12 added to the residue. The resultant solution was then dried with anhydrous K2C03 and passed through SOg of basic alumina (Wolem Super I)*
Most of the CH2C12 was then removed under reduced pressure and one liter of diethyl ether added to the resultant syrup. The ether was 2o removed by distillation and additional diethyl ether added to cause precipitation. The mixture was stirred at room temperature for two hours and then filtered to give 45 g of alpha-(2-chloroethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7 Anal. Calcd for C3H7C10(CH2CH20)111.7 C,53.97; H,9.12; C1,0.71.
Found: C, 54.21 H,8.70; C1,0.71 B. Preparation of alpha-f2-Azidoethvl)-omega methoxy~oly (ox 1,2-ethanedivl) SRU 111 7 A mixture of 20g of sodium azide and SOg of alpha-(2-chloroethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7 was heated at 120-125°C in 375 ml of dry DMF. After 7 hours the solvent was removed under high vacuum. The residue was dissolved * Trademark ~~~3~~~

in 500 ml of CH2C12 and filtered through diatomaceous earth. Most of the CH2C12 was then boiled off and diethyl ether added to cause precipitation. The mixture was stirred overnight and then filtered.
The residue was then dissolved in a minimum of glyme at 50°C, the solution cooled, and the precipitated product filtered to give alpha-(2-azidoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl.) SRU 111.7 Anal. Calcd for C3H3N3O(CH2CH2O)111.7: 0,53.77; H,9.09; N,0.84.
Found: 0,53.61; H,9.08; N,0.89.
C Preparation of alpha-!2-AminoethylZomega-methoxypoly_ (ox~!-1.2-ethanedi~) SRU 111.7 To a mixture of 25g of alpha-(2-azidoethyl)-omega-methoxypoiy (oxy-1,2-ethanediyl) SRU 111.7 in 250 ml of dry glyme was added 3.5 g of I0% Pd/C. The mixture was then placed under an atmosphere of 50 p.s.i. of H2 and shaken at 50°C for 18 hours. The mixture was then filtered, the solids washed with CH2C12 and the combined organic solutions placed under reduced pxessure to remove the solvent. The residue was then dissolved in 100 ml of warm glyme, and the product allowed to precipitate from the cooled solution. The, precipitate was 2o filtered and dried by warming under reduced pressure to give 23g of alpha-(2-aminoethyl)-omega-methoxypoly {oxy-1,2-ethanediyl) SRU
111.7 n~. Calcd for C3H9N0(CH2CH20)111.~: C,S4.43; H,9.20; N,0.28.
Found: 0,54.43; H,9.18; N,0.36.
Alternatively a solution of 40g of alpha-{2-azidoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7 and 6.7 g (25.6 mmol) of triphenylphosphine dissolved in 200 ml of dry CH2C12 was stirred overnight under an atmosphere of argon. Water (2m1) was added and the mixture stirred an additional 12 hours. Most of the methylene chloride was removed under vacuum and 400 ml of diethyl ether added. The precipitate was filtered, washed with ether and dissolved in 300 ml of warm (50°C) glyme. The solution was allowed to stand at room temperature overnight and the resulting precipitate filtered, r 20~3~86 washed with 2x100 ml of glyme, 2x100 ml of diethyl ether and dried in a vacuum oven under a stream of N2 to give 35g of alpha-(2-aminoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7 l~ Preparation of alpha-f 2-f f (C c~xylamino)thiocarbonyll-aminolethvll-omega-methoxypol~fox rte- Y2-ethaned~l) SRU 111 7 To a solution of 4g of alpha-(2-aminoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7 in 60 ml of dry glyme at 40°C was added 0.1 ml of cyclohexyl isothiocyanate. The solution was allowed to stir at 40°C for 18 hours. The mixture was then filtered and the solvent removed under high vacuum. The residue was then dissolved in 100 ml of warm glyme, the solution cooled and the resulting precipitate filtered and dried under high vacuum to give 3.5g of alpha-[2-[[(cyclohexylamino)thiocarbonyl]-amino]ethyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 111.7 Anal. Calcd for ClpH2pN2(DS(CH2CH20)111.7: C,54.25;
H,9.13; N,0.54; 5,0.62; Found: C,54.39; H(,8.87; N,0.55; 5,0.59.
E. Preparation of alpha-f2-ff(C cLlohe_oYlcarbonimidoyl)aminol-ethvll-omeea-m_ tg hoxv~,ol~(o~c~,~ 1 2-ethan~~~liYlyRU 111.7.
A solution of 1 g of alpha-[2-j[(Cycl~hexylamino)-thiocarbonyl]amino]ethyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 111.7, 120 mg of triphenylphosphine, 90 p.1 of CCl4 and 84 p,1 of triethylamine in 5 ml of dry CH2Cl2 was refluxed for 72 hr. The solvent was then removed under reduced pressure and the residue dissolved in a minimum of dry glyme. After cooling, the product precipitated and was filtered and dried under vacuum to give alpha-[2-[[(cyclohexylcarbonimidoyl)amino]ethyl]-omega-methoxypoly-(oxy-1,2-ethanediyl) SRU 111.7.
Anal. Calcd for C10H18N20(CH2CH20)111.7: 054.61; H,9.15;
N,0.55. Found: C,54.95; H,9.27; N,0.50.

~~v3886 I'renaration of al~aha-i2-Chloro~]gyp ~nnethoxp_holvioxv-1.2-ethanec ~ll~ll ,,SlRy1 225 .
By the procedure described in Example 1A, MPECi molecular weight 10,000 was converted to alpha-(2-chloroethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 225.
Anal. Calcd for C3H7C10(CH2CH20)225: 0,54.37; H,9.14; 01,0.35.
Found: 0,54.30; I-I,9.15; 01,0.41.
Examgle 1b lar~naration of aloha-i2-Azidoethvl)-omega-methoxvnolvioxv-1.2-ethanedi~l) SRU 225 By the procedure described in Example 1B, alpha-(2-chloroethyl)-ornega-methoxypoly(oxy-1,2-ethanediyl) S;RU 225 was converted to alpha-(2-azidoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU
225.
Anal. Calcd for C3H7N30(CH2CH20)22g: 0,54.34; H,9.13; N,0.42.
Found: 0,54.32; H,9.28; N,0.50.
Ex~m~ 1~ a 1 it Pr~~aration of alpha-f2-Aminoethull-ome~a-methoxvuol ox -~-ethanedivl) SRU 225 By the procedure described in Example 1C, alpha-(2-azidoethyl)-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 225 was converted to alpha-(2-aminoethyl)-omega-rnethoxypoly (oxy-1,2-ethanediyl) SRU
225.
Anal. Calcd for C3H9N0(CH2CH20)225: 0,54.48;-.--- I3,9.17; N,0.14.
Found: 0,54.80; H,9.21; N,0.12.

2~~3~~~
- 27 _ Preparation of alnaha-(2-f hl,gg~oQth 1)-om g"~~.~aep,~olv (oxv-1 2-ethanediRU 28 ~
To a solution of freshly distilled oxalyl chloride (0.5 ml) in 40 ml of dry CH2C12 at 0°C was added dropwise 0.5 ml of dry DMF in 10 t o rnl of CH2C12. The resulting solution was warmed to room temperature, stirred for 15 min and then again cooled to 0°C. Ml'EG
molecular weight 1325, (5.6 gr) was then added, and the resulting solution refluxed for 5 hr. The mixture was then poured into water and the mixture extracted with CH2C12. The CH2C12 solution was dried ( Mg S ~4) and the solvent removed under reduced pressure to give 1.7 g of alpha-(2-chloroethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 28.3 as a white powder.
Anal. Calcd for C3H7C10(CH2CH20)2g,3; 0,53.38; ~I,9.03; 01,2.64.
Found: 0,53.48; H,9.10; 01,2.41.

By the procedure described in Example 1B, alpha-(2-chloroethyl)-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 28.3 was converted to alpha-(2-azidoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 28.3.
Anal. Calcd for C3H7N30(CH2CH2~)28.3: C,S3.12; H,8.99; N,3.11.
Found: 0,53.21; H,9.07; N,2.98.

- 2g - 2063~~6 By the procedure described in Example 1C, alpha-(2-azidoethyl)-omega-methoxypoly(oxy-1,2-ethanediyl) SItU 28.3 was converted to alpha-(2-aminoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU
28.3.
Anal. Calcd for C3H9N0{CH2CH20)2g,3: 0,54.47; H,9.17; N,0.14.
Found: 0,54.44; H,9.19; N,0.15.
Pre,~aration ~f Idecomhinant Interferon-nI~IFN-alpha) Conin~ated to P~EC by means of the reagent a ~2-~~~lo~hea~~,vlcarbonimido"g]~aminol-et vll-omega-ntethox~g~,ol~oxv-1,2-ethanediy~,~~tIJ 1117 alpha-[2-[[(Cyclohexylcarbonimidoyl)amino]ethyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 111.7 prepared according to Example 1 was added to 1 mg of homogenous IFN-alpha in 200 u1 of buffer (0.1 M sodium borate, pH 9.0) in a molar ratio of 10 moles of reagent per one mole IFN-alpha. The solutions were thoroughly mixed and the pegylation reaction allowed to praceed at room temperature for 60 minutes.
The amount of derivatization (or pegylation) of IFN-alpha was estimated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 3 o (TABLE 1 ). Proteins were visualized by Coomassie Blue staining.
Analysis of the products from the 60 min. reaction reveals new higher molecular weight protein species corresponding to PEG-conjugated I>rIV-alpha. IFN-alpha has an apparent molecular weight of 15 kD by SDS-PAGE. Unmodified IFN-alpha whose apparent molecular weight 20~3~~6 remains unchanged is therefore not conjugated with PEG. The PEG-modified IFN-alpha product has an apparent molecular weight of 28 kD.
TABLE I: Modification of IFN-alpha with the reagent described in Example I
Ap-parent Molecular We~ht of % of Total Protein IFN Protein ~,kDl from Reaction 15 (unmodified) 80 Fxamp>le 3 Preparation of Recombinant InterleikW.2 lr~l.z) ~p~iu~ated to PPti be means of the reag ne._t a~ha-[~
f((f,~vclohexvlcarbonimidovllaminolethvl, 1-omega tnethvoxv~nolv(oxv-1.2-ethaned;"vll SRL1 111 _7_ Alpha-[2-[[(cyclohexylcarbonimidoyll]amino]ethyl]-omega-2o methoxypoly(oxy-1,2-ethanediyl) SRU 111.7 prepared according to Example 1 was added to 2 mg of rIL-2 in 200 u1 of buffer (0.1 1VI
sodium borate, pH 9.0) in a molar ratio of 10 moles of reagent per one mole rIL-2. The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes.
The amount of derivatization (or pegylation) of the protein was estimated by SDS-PAGE (Table II). Proteins were visualized by Coomassie Blue staining. Analysis of the products from the 60 min.
reaction reveals new higher molecular weight protein species corresponding to PEG-conjugated rIL-2. rIL-2 has an apparent molecular weight of 15 kD by SDS-PAGE. Unmodified rIL-2 is the protein separated from the reaction mixture whose molecular weight remains unchanged and is therefore not conjugated with PEG. The predominant PEG-modified rIL-2 product has an apparent molecular weight of 28 kD.

TABLE II Modification of rIL-2 with the reagent described in Example 1 Apparent Molecular Weight of % of Total Protein rIL-2 Protein tkD) from Reaction (unmodified) 20 to Pegylated rIL-2 was purified from the reaction mixture as described by Katre et al. [Proc. Nat. Acad. Sci., USA, x:1483-1491, (1987)) using hydrophic exchange chromatography (Bio-Rad; Biogel*
phenyl 5-PW). A linear gradient with decreasing salt from 1.53 to 0.0 15 M (NH4)2S04 in 50 mM sodium phosphate pH 7.0 in 30 minutes was used to separate PEG-modified and unmodified rIL-2. Aliquots of the fractions were evaluated by SDS-PAGE and pooled fractions were assayed to determine its specific activity in a CTLL cell proliferation assay by the method described by Gillis et al. [J. Immunology 120:2027-2032, (1978)). Protein concentrations were determined spectrophotometrically at 280 nm using an extinction coefficient of 0.667 for rIL-2. The specific activity of the rIL-2 isolated proteins is expressed as units/mg protein and the results are summarized in Table III. It is apparent that specific activity of rIL-2 is not significantly altered by conjugation with PEG.
TABLE III. Bi activit of rIL-2 c n' to o PE with the rea ent described in Exam 1e 1 3o Apparent Molecular Wei hr of Specific Activity rIL-2 Protein fkD) (units/rr 1 1 S (unmodified IL2) 2.0 x 107 28 2.4 x 107 * Trademarlk -.

~flfl~8~6 Prenarat~~ of Recombinant Interleukin -alpha (rI -1 >lSCvslohe~~lcarboni~nido9,~,larninoley~" ll~ome~a methoxv~pl~lone,~~ethanediyl) SR~111~.7.
The reagent described in Example 1 was added to 2.0 mg of homogenous rIL-1 alpha in 1.0 ml 0.1 M sodium borate, pH 9.0 in a molar ratio of 10 moles of reagent per one mole rIL-1 alpha. The solution was thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes.
The amount of derivatization . (or pegyiation) of the protein was estimated by SDS-PAGE (Table IV). The proteins were visualized by Coomassie Blue staining. Analysis of the products from the 60 minute reaction reveals new higher molecular weight protein species corresponding to PEG conjugated rIL-1 alpha protein. rIL-1 alpha has an apparent molecular weight of 17 kD by SDS-PAGE. Unmodified 2G rIL-1 alpha is protein from the reaction mixture whose apparent molecular weight remains unchanged and is therefore not conjugated with PEG. The PEG-modified rIL-1 alpha product has an apparent molecular weight of 30 kD.
TABLE IV. Modification of rIL-1 a~ha with the reagent described in Example 1 Apparent Molecular Weight of % of Total Protein rIL-1 alpha Protein (kD) from Reaction 3 o 17 (unmodified) g5 20~~8~6 Preparation of s~,Rha~j~,,~-Dihvy-2-~xo-1-nvridin,~-thiocarbon 1-omega~methoxy o~le(oxv-l.~.ethanediy,ll SItL1 11.7 From a solution of 1 g (0.2 mmol) IVIPEG (methoxypolyethylene glycol) molecular weight of 5000, in 15 ml of dry toluene was distilled 5 ml of solvent. The resulting solution was cooled and 46.5 mg (0.2 o mmol) of 1,1-carbonothioylbis-2(1H)-pyridinone was added. The mixture was then refluxed under an atmosphere of argon for 4 hours.
The solvent was then removed under vacuum and the residue dissolved in 5 ml of dry glyme and let stand overnight. The resulting precipitate was then filtered and washed with 2x5 ml of dry glyme and 5 ml of diethyl ether. The product was then dried in a vacuum oven under a slow stream of nitrogen to give 0.96 g of alpha-[(1,2-dihydro-2-oxo-1-pyridinyl)thiocarbonyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 111.7.
Anal. Calcd for C9H11N03S(CH2CH2t~)111.7~ 0.54.37; H,8.99;
N,0.27; 5,0.62; Found: 0,54.03; H,8.98; N, 0.18; 5,0.59.
Exam~~~
Preparation ofylz~ha-f(1 2-jP"j,heyyo-2-oxo-1- ri i~ll-thiocarbony lom ,~.a-vplgth~xv~Ol_lrfoxy-1.2-ethanedi~rll SRL1 By the procedure described in Example 5, MPEG (methoxypoly-ethylene glycol) molecular weight 10,000 was converted to alpha-[(1,2-dihydro-2-oxo-1-pyridinyl)thiocarbonyl~-omega-methoxy-poly(oxy-1,2-ethanediyl) SRU 225.
Anal. Calcd for C9H11N03S(CH2CH2~)225: 0, 54.54; H, 9.08; N, 0.14; S, 0.32. Found: C, 54.38; H, 9.16; N, 0.15; S, 0.31.

- 33 - 20~3~~6 elation of Interle'akin 1 rece~r antagonist (Ii .~tral unmitigated to I'E($ by means of the rea~Pnt . a~~.i(1 2-I)ihvdro-2-oxo- -~"vridinyj?tl~iosarborL~, lotne~a-~yV.
-(ox~r-1.2-ethaned~al SRU 1 i 1 7 Alpha-(( 1,2-dihydro-2-oxo-1-pyridinyl)thiocarbonyl]-omega-methoxy-poly(oxy-1,2-ethanediyl) SRU 111.7 prepared according to Example 5 was added to 10 mg of homogenous II,-lra in 1.0 ml of buffer (0.1 M sodium borate, pIi 9.0) in a molar ratio of 5 moles of reagent per one mole of IL-lra. The solution was thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes.
The amount of derivatization (or pegylation) of the protein was estimated by SDS-PAGE (Table V). Proteins were visualized by Coomassie Blue staining. Analysis of the products from the 60 minute reaction reveals new higher molecular weight protein species corresponding to PEG-conjugated IL-lra protein. IL-lra has an apparent molecular weight of 19 kD by SDS-PAGE. Unmodified IL-lra is the protein from the reaction mixture whose apparent molecular weight remains unchanged and is therefore not conjugated with PEG.
The predominant PEG-modified IL-lra proteins have apparent molecular weights of 26 and 33 kD.

TABLE V. lVlodification of IL-lra with the reagent described in Example 5 Apparent ll~olecular Weight of %of Total. Protein IL-lra Protein lkDl from_ Reaction 19 (unmodified) 36 >33 10 Pegylated IL-lra was purified from the reaction mixture using hydrophobic exchange chromatography (Bio-Rad; HRLC lYiP? HIC). A
linear gradient with decreasing salt concentrations from 0.43 to 0.0 1~II
(NH4)2S~4 in 50 mM sodium phosphate pH 7.0 in 20 minutes was used to separate pegylated IL-lra and unmodified IL-lra. Aliquots of fractions were evaluated by SDS-PAGE and pooled fractions were assayed in an IL-1 radioreceptor competition binding assay. (lKilian et al. J. Imrnunol., 13 , 4509-4514, (1986)]. Briefly, IL-lra and PEG-IL-lra were incubated at varying concentrations with EL-4 membranes 2U for 30 min at 37°C. The (1251]IL-1 alpha was then added and the incubation continued for 30 min. The assay was terminated by vacuum filtration and the collection of cell bound [1251]IL-1 on filter plates. The concentration of IL-lra or PEG-IL-lra that inhibits binding of (1251]IL-1 by 50%'0 (IC50) was determined graphically. The results are shown in TABLE VI. The IC50 of IL..lra in this assay is 1-2.0 ng/ml. The pegylated IL-lra mixture retained its ability to bind to the IL-1 receptor on EL-4 membranes within a factor 2 to 3 fold relative to the unmodified Il-lra.

TABLE VI. Inhibition of f 125I1 IL_1 Binding, b~ of IL-lra Con'~uga, ted with the reagent described in Example 5 Apparent Molecular ~Vei~,ght of .
IL-lra Protein fkDl ICSp n ml 19K (unmodified) 2.0 26K, 33K (mixture) 5.0 The pharmacodynamics of IL-lra protein was evaluated in vivo by the ability of the IL-lra to inhibit rIL-lalpha induction of interleukin-6. Serum from mice treated with rIL-lalpha contain high levels of IL-6, [McIntosh et al., Immunol. 143: 162-167, (1989)]. The administration of unmodified IL-lra together with IL-lalpha (0 hr time point) inhibits the induction of IL-6. This test system was used to compare the pharmacodynamie properties of unmodified and PEG
iL-lra. Groups of three female C57B1/6 mice were injected subcutaneously with 200 ug of unmodified IL-lra or PEG-IL-lra 48 hr, 24 hr, or 6 hr before or simultaneously (0 hr) with 0.2 ug rIL-1 alpha. Three hours later, serum samples were collected. IL-6 levels z0 (units) were determined using a modification of an IL-6 assay that has been previously described [Van Snick et al., Proc. Natl. Acad. Sci.
USA x:9679-9683, (1986)]. In the IL-6 .assay, B9 hybridoma cells were treated with two fold serial dilutions of the test sera in 96-well microtiter plates. Following a 3 day incubation at 37°C in a humidified 2s atmosphere comprised of 5%~ COZ and 9-'i% air, the wells were pulsed with 0.5 uCi of tritiated thymidine and incubated for an additional 18 hr. The cells ware then harvested onto glass fiber filters and the level of tritiated thymidine incorporation was determined ~ by scintillation counting. IL-6 activity is expressed as U/ml. IL-6 units are defined as 3o the inverse of the serum dilution which produces half-maximal tritiated thymidine incorporation compared to a reference standard.
The pharmacodynamic data are summarized in Table D1. Mice treated only with IL-1 exhibited 28852 U/ml IL-6. Both unmodified ~Q~J~~~

and modified IL-lra inhibited IL-6 induction at 0 hr, k~Iowever, the pegylated IL-lra demonstrated a prolonged IL-6-inhibitory effect as compared to unmodified IL-lra at 8 and 24 hours after administration.
TABLE D1. Pharmacodvnamic Profile of iL-lra oniu~ated with the reagent described in Example 5 Time (hr.) Prior to IL-6 (Units/ml) IL-1 Administration 19 kD 26 kD

72 . 13220 21470 ~xaml la a 6~, P~e_,n_a~ration of Interleg~g 1 recg~,o_r antagonist (I1.-' coniu~~ted to p .1'~p~lns of thg_reag n a h L1~ dra-2-oxo-i ~ ridanlr] thio'on;vll-Qme~~-~fhoxva~olv-(oxw-1. -etl~a_n~~iYI.L~L~ 225.
IL-lra was conjugated and purified according to the procedure illustrated in Example 6 using the reagent described in Example 5a.
The predominant PEG-modified IL-lra proteins have apparent 3o molecular weights of 33 kD and 48 kD. The 33kD and 48 kD protein accounted for 46 and 27% of the total protein in the reaction mixture, respectively.

The ability of these proteins to inhibit IL-1 binding, as described in Example 6, is summarized in Table VII. The 33kD PEG modified protein retains the ability to inhibit TI,-1 binding within 6-fold relative to IL1-ra and more extensive modification ~ of the protein with PEG as observed with this 48kD protein results in a substantial loss in its binding to the IL-1 receptor.
'TABLE VII. Inhibition of (125 Il IL-1 Bindine by IL-lra Proteins Conjugated with the rea e;~~ nt described in Example Sa Apparent Molecular Weight of IL-lra Protein ~IrD~ I~50 n ml 19 (unmodified) 1.6 33 g,0 48 50.0 To determine the pharmacokinetic profile of PEG-IL-Ira species, C57BF/6 mice were administered 100 ug of modified or pegylated IL-lra species subcutaneausly. Serum samplers were collected after 1, 2, 3, 4 and 6 hours from mice that received unmodified IL-lra and after 2, 4, 8, 10, and 24 hours from mice that received PEG-IL-lra. The serum levels were determined in the EL4 membrane binding assay described in Example 6. The data are summarized in Table D2. The PEG-IL-lra was detectable in serum samples at higher concentrations and for prolonged time compared to IL-lra demonstrating a prolonged serum time course.

2~~3~~~
- 3g -TABLE D2. Pharmacokinetic Profile of IL-lra peg~late_d as in Example 6a Serum Concentration of IL-lra Time Ehr.) After Administration 19 kD 33 kD

~

'I 15 g00 1 S 2~. 15 Prena a ion of rIL-'! alpha c~n~.~Q~tod to P .r by means ~f the reagent a'~LiLills-i(1~--2-dih,~;~2-oxo-1-,~Y.Ll~~llt~,-thrgcar~ al mega-m ~x"~~ot.~(o.,~y~1.2-ethanedi~rl) SRLI
112.7.
Recombinant IL-1 alpha was pegylated with the reagent described in Example 5 by the method as described in Example 4.
Three predominant molecular weight species from the reaction mixture were identified by SDS-PAGE with apparent molecular weights corresponding to 17 (unmodified), 26, and 33 kD. The latter two pegylated proteins accounted for 25 and 55% of the total protein, respectively.
Pegylated rIL-1 alpha was purified from the reaction mixture after 60 minutes using hydrophobic exchange chromatography (Bio-Rad; HRLC MP7 I~IC). A linear gradient with decreasing salt concentration from 0.43 to 0.0 M (1VH4)2SC34 in SO mM sodium phosphate pH 7.0 in 20 minutes was used to separate pegylated rIL-1 alpha and unmodified rIL-1 alpha. Aliquots of fractions were evaluated by SDS-PAGE and pooled fractions were assayed for specfic activity in a D10 cell proliferation assays by the method described by Kaye et al. [J. Exp. Med. 158:836-854 (1983)]. Protein concentrations were determined spectrophotometrically at 280 nM using an extinction coefficient of 1.0 for rIL-1 alpha. The specific activity of the rIL-1 alpha is approximatelyl.0 x 108 units/mg. The specific activity results are summarized in Table VIII. The 26kD pegylated IL-1 alpha conjugate retains bioactivity within 2-3 fold of relative to IL-1 alpha.
Further modification resulting in a 33kD protein results in substantial loss of bioactivity.
TABLE VIII. Bioactivitv of rIL-lalpha ~on'~u~ated with the reagent described in Example Apparent Molecular Wei hg t of Specific Activyr rIL-1 alpha Protein (kD) (units/mel 17 (unmodified) 4.6 x 107 26 1.9 x 107 33 4.S x 106 30 alpha-[(1,2-Dihydro-2-oxo-1-pyridinyl)thiocarbonyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 111.7 prepared according to Example 5, was added to 1 mg of purified IFN-alpha in 100 u1 of buffer (0.1 M sodium borate, pH 9.0) in a molar ratio of 8 moles of the PEG reagent per one mole IFN-alpha. The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes.
The predominant molecular weight species from the reaction mixture were identified by SDS-PAGE with apparent molecular weights of 15 (unmodified), and 28 kD. The 28 kD pegylated protein accounted for 40% of the total protein.The pegylated IFN-alpha was purified from the 60 minute reaction mixture and characterized using hydrophobic exchange chromatography (Bio-Rad; Biogel*phenly-S-PW). A linear gradient with decreasingsalt concentrations from 0.42M

to 0.0 M (NH4)2S 04 in 50 mM sodium phosphate pH 7.0 in 20 minutes was used to separate pegylated IFN-alp ha and unmodified IFN-alpha.

Aliquots of the fractions were evaluatedby SDS-PAGE and pooled fractions were assayed for anti-viral activity (specific activity) in an ~ 5 MDBK assay by the method described by Familletti, et al. [Methods in Enzym. 78,387-394 (1987)].

Protein concentrations were determined spectrophotometrically at 280 nM using an extinction coefficient of 1.0 for a 1 mg/ml IFN-2o alpha buffered solution. The specific activity of the isolated proteins is expressed as units per mg protein and the results are summarized in Table IX.
The results show that the specific activity of the 28kD pegylated 25 IFN-alpha was not significantly altered relative to IFN-alpha.
TABLE IX. Bioactivitv of IFN-alpha Coniu~ated with the reagent of Example 5 3o Apparent Molecular Wei hg t of Specific Activity IFN-alpha Protein (kD) (units/mQl (unmodified) 1.1 x 108 2 8 1.4 x 108 * Trademark ~4~38~~

Preparation of IFN al h~ ~ co~~gated to Ph~ by means of the reagent alpha-f(I.2-Dih~,vdro-2-mxo-1-~r~'di~r~ll-thioearbonvllom~ga-methoxv,_~ol" -~y-1 2-ethanedi~L SIZI1 225~
Il=N-alpha was pegylated as in example 8 with the reagent described in Example 5a. Three predominant molecular weight species from the reaction mixture at 60 minutes were identified by SDS-PAGE
with apparent molecular weights corresponding to 15 (unmodified), 35 and 43 kD. The latter two pegylated proteins accounted for 35 and 33 per cent of the total proteins in the reaction mixture, respectively.
The specific activities determined by procedures described in Example 8 of the pegylated species of IFN-alpha are summarized in Table X. The results show that the 35kD pegylated IFN-alpha product retained biological activity within 2-3 fold of IhIV-alpha. The 43kD
conjugate lost substantial activity.
TABLE X Bioactivitv of IFl~-alpha Conju~:ated with the rea ent of Example 5t!
Apparent Molecular Wei hg t of Specific ActivitX
IFN-alpha Protein (kDy (units/m,~l 15 (unmodified) 3.3 x 108 1.2 x 108 43 1.5 x 10~~

2~~3~~6 yxamnle ~~pen al ha- (j, .Di fro-2.oxo.1-nr ridinvll.
jLl.7 rIL-2 was pegylated with the reagent described in Example S and purified using the procedure as described in Example 3.
The predominant molecular weight species from the reaction mixture after 60 minutes were identified by SDS-PAGE with an apparent molecular weights of IS (unmodified) and 25 kD. The 2S kD
pegylated protein accounted for 60% of the total protein in the reaction.
The specific activity of the rIL-2 isolated proteins were measured as described in Example 3 and is expressed as units/mg protein and the results are summarized in Table XI.
As can be see in Table XI, the biological activity of IL-2 was not altered after conjugation with PEG.
TABLE XI. Bioactivi~ of rIL-2 Con'uea~ted to PEG with the reagent described in Example 5 Apparent Malecular Weight of Specific Activi rIL-2 Protein tkDl 4units/m;~,l IS (unmodified) 2.0 x 10~
3 0 25 2.0 x I 0~

~06~88~

Prer~aration of rli.-2 conjugated to PE(g ib,~ nr~eans of the ~~~~alnha-f f 1.2-Dihvdro-~,-oxo-1-~vridinvll-rIL-2 was pegylated using the procedure described in Example 3 with the reagent described in Example Sa.
The predominant molecular weight species from the reaction mixture after 60 minutes were identified by SDS-PAGE with apparent molecular weights of 15 1cD (unmodified), 33 kD, and 43 kD. The 33 and 43 1cD pegylated proteins accounted for ~0 and 20 per cent of the t 5 total protein in the reaction, respectively.
Pre~ration og Fr1-al h~cspj~y,~atat~ to P'E~f: by I means of ti,~

dent aloha-f (1.2-~ihydro-2-nxc'-1-~vridirivl)-thiocarbon~l_,o ~~,ga-m~~,thox -nolv~Q,g,v-1.2-ethanedi ~ 1 ~It ~
J-1L.~

.

An alternative method for conjugating 1'.FN-alpha to PEG was done as follows:
IFN-alpha (5 mg in 1 ml) was dialyzed against a buffer containing 5 mM sodium acetate, pH 5.0, 120 mM NaCI. To the dialyzed protein solution, solid potassium thiocyanate was added to obtain a final 3o concentration of 0.5 M salt, and the pH adjusted by the addition of one-tenth volume of 1 M tricine-sodium hydroxide, pH 11.9 to give a final pH 10.0 solution. alpha-[(1,2-Dihydro-2-oxo-1-pyridinyl)thiocarbonyl]-omega-methoxypoly(oxy-1,2-ethanediyl) was added to the sample at a molar ratio of 3 moles of reagent to 1 mole of protein. The modification reaction was allowed to proceed at room temperature for 30 minutes, and stopped by the addition of 1 M
glycine, pH 6.3 to a final concentration of 20 mM. PEG-modified protein was precipitated from solution by addition of a buffer containing 3.5 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0 to a final concentration of 1.1 M ammonium sulfate and the precipitate collected by centrifugation (10,000 x g for 12 min.). After rinsing the pellet with a buffer containing 1.1 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0, the pellet was redissolved in a buffer containing 25 rnM ammonium acetate, pH 5Ø The PEG-modified protein was purified and characterized as described in Example 2. A single pegylated IFN species was obtained with an apparent molecular weight of 28 kD. Antiviral activity specific activity) of the modified protein was determined by the procedure described in Example 8. The specific activity of the starting IFN-alpha was 2.6 x 108 U/mg and the specific activity of the IFN-alpha conjugated to PEG was 1.0 x 108 U/mg demonstrating that the PEG
conjugated IFN-alpha retained biological activity within 3-fold relative to II~N-alpha.
Exam In a _1_~Q
Pr~naration of 1FN-al ~ conjggated to PE . by means of the reagent alpha-rfi 2-I)ij~adro-2-oxo-1-~, ridin >~-thiocar-bonvll-otne~a-methox~~l,vw-1 2-ethanedivll SRU 225.
IFN-alpha was conjugated to PEG according to the procedure described in Example 9. The proteins were purified and characterized as described in Examples 2 and 9. The starting IFN-alpha had a 3o specific activity of 2.6 x 108 U/mg using the IFN-alpha conjugated to PEG which has an apparent molecular weight of 31 kD and had a specific activity of 1,0 x 108 U/mg as described in Example 8. The bioactivity of the conjugated IFN-alpha was within 3-fold of IFN-alpha.

~a~~~~~

Preu~ration of allaha-lYdethvl-omeg . ._rrr~.)~~ridin loxv) ~r~onvllaminoiethoxvl~lRf~ _v 1 ,2,.~thanedivl~U a11_7_ From a solution of 1 g (0.2 mmol) of alpha-(2-aminoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7 (as prepared in Example 1C) in 40 ml of dry CH2Cl2 was distilled 15 ml of solvent. To 1 o the resulting solution at 0°C was then added 65 mg (0.3 mmol) of di-2-pyridyl carbonate and the mixture stirred for an additional 4 hours.
The solvent was then removed under reduced pressure and the residue triturated with diethyl ether. The precipitate was then filtered and washed with 50 ml of ether followed by 50 ml of hexane.
The product was then dried in a vacuum oven under a slow stream of nitrogen to give 1 g of alpha-methyl-omega-[2-[[{2-pyridinyloxy)carbonyl]amino]
ethoxy]poly(oxy-1,2-ethanediyl) SRU 111.7. as a white powder.
Anal. Calcd for C9H12N20g(CH2CH2fJ)111.7~ 0,54.56; H,9.04;
N,0.55; Found: 0,54.26; H,9.00; N,0.53.
Exam 11~~ a _ll.~
]Preparation of all]~vt_~~~.p, r' i n~ loxv) ~~rbomrllaminolethox~l~olv(oxv 1 2;_ ~thanedivll ~R 1 22S
By the procedure described in Example 11, alpha-(2-aminoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 225, (as prepared in Example 1c) was converted to alpha-methyl-omega-[2-[[(2-pyridinyloxy)carbonyl]amino]ethoxy]poly(oxy-1,2-ethanediyl) SRU 225.
Anal. Calcd for C9H12N243(CH2CH20)225: C, 54.54, H, 9.10; N, 0.28. Found: C, 54.49; H, 9.27; N, 0.31.

s Ey the procedure described in Example . l 1,.. alpha-(2-amino-ethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 28.3 (as prepared in Example 1f) was converted to alpha-methyl-omega-[2-[ [(2-pyridinyloxy)carbonyl]-amino]ethoxy]poly(oxy-1,2-ethanediyl) 1 o SRU 28.3.
Anal: Calcd far C9H12N203(CH2CH20)2g,3: C, 54.61; H, 8.75; N, 1.94. Found: C, 54.67; H, 8.96; N, 1.63.
2o alpha-Mfethyl-omega-[2-[[(2-pyridin;yloxy)carbonyl]amino]-ethoxy]poly(oxy-1,2-ethanediyl~ SRU 111.7, was added to 2S mg of purified IL-lra in 2.S ml of buffer (0.1 M sodium borate, pH 9.0) in a molar ratio of 1 mole of reagent per one mole of II,-lra. The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes. PEG modified ILra was then purified according to the procedure set out in Example 6.
The predominant pegylated products from the 60 minute reaction had apparent molecular weights of 28 kD and 38 kD and accounted for approximately 42 and 29% of the total protein from the reaction mixture, respectively.
The ability of the purified IL-lra proteins from the reaction mixture to inhibit IL-1 binding was determined as described in Example 6 and summarized in Table XII. The binding properties of the 28kD product was not significantly altered and the bindability of the 38kD protein retained activity within 5-fold of IL-lra.
TABLE XII. Inhibition of (125I1-IL-1 Bindin~bv IL-lra Protein Pe~vlated with the reagent described in Example 11 Apparent Molecular Weight ~f iC_~0 IL-lra Protein (kD) n ml l0 19 (unmodified) 2.0 28 3.0 38 10.0 The pharmacodynamic profile of PEG-IL-lra was determined as described in Example 6. The data are summarized in Table D3. IL-1 alone induced 27283 u/ml of IL-6. Unmodified IL-lra inhibited less than 50% of the IL-1 response within 6 hours of administration. In contrast, PEG IL-lra although less activt; at early time points, was much more active at 24 and 48 hours after injection. Thus, the PEG-2U IL-Ira exhibited a prolonged pharrnacodynamic profile.
'_1'ABLE D3 Pharmacodynamic Profile of IL-lra Conjyted with the reagent deSCribed in Example 11 Tirrte_ (hr.) Prior to IL-6 Units/ml IL-1 Administration 19 kD 26kD

Exam l~
Pr r i n f I -lr PE an n f hh reagent alpha-Methvl-omega-f2-ff(2-,pvridinvloxv)-car n 1 min h x 1 x -1 2- h n i ~I R 22~
alpha-Methyl-omega-[2-[[(2-pyridinyloxy)carbonyl]aminoJ-ethoxy)poly(oxy-1,2-ethanediyl) SItU 225, (previously described in Example Ila) was added to 25 mg of purified IL-lra in 2.5 ml of buffer (0.1 M sodium borate, pH 9.0) in a molar ratio of 4 moles of 1 o reagent per one mole of IL-lra. The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature far 60 minutes. PEG modified IL-Ira was then purified according to the procedure set out in Example 6.
The predaminant pegylated products from the 60 minute reaction had apparent molecular weights of 33 kD and 48 kD and accounted for approximately 76 and IS% of the total protein from the reaction mixture, respectively. The ability of the purified IL-lra proteins from the reaction mixture to inhibit IL-1 binding are summarized in Table XIII. The 33kD PI:G modified protein retained its ability to inhibit IL-1 binding within 8-fold relative to IL-lra. The 48kD product lost substantial binding capacity.
TABLE XIII. Inhibition of (12~I IL-1 B_'rndin~ by IL-Ira Proteins Peevlated with the reaeent described in Example 11 a Aonarent Molecular Wei hg- t of IL-lra Protein (kD) ICAO n ml 19 (unmodified) O.g 33 6.0 48 18.0 The pharmacokinetic profile of PEG-IL-Ira was determined as described in Example 6A. The data are summarized in Table D4. The 20~3~~~

PEG-IL-lra was detectable in serum samples at higher concentrations and for a prolonged tune compared to the unmodified IL-lra.
TABLE D4. Pharmacokinetic Profile of IL-lra Gonju a~ ted with the reagent described in Example 11 a Serum Level of IL-lra (ne/ml) Time (hr.) lifter Administration 1 kD kD
4 ~ 5.3 5 6 1.5 Examlye 1,~
Preuaration of rI ,-2 c~,~j~,gs~tyL t~u~.~~9ean,s rea~e~I al~h_a_-t~et yp~~ga f ff(2-Rvridinyloxvl-c~rbotavll~minolethoxvla~~Ivfoxv-1 2 a~Lh~~ll. SItL1 113 _~' rIL-2 was pegylated with alpha-methyl-omega-[2-[[(2-pyridinyloxy)carbonylJamino]ethoxy]poly(oxy-1,2-ethanediyl), SRU
111.7, according to the procedure set forth in Examples 3 and 8b. The specific activity of the IL-2 protein was determined as described in 3o Example 8. The specific activity of the 15 kD unmodified rIL-2 was 2 x 107 units/mg and of the 29 kD pegylated IL-2 was 2.4 x 107 units/mg IL-2 indicating no substantial loss of biological activity as a result of pegylation.

20~3~~6 -Y
by means of the reagent alg~h, -t yl-omega-t2_rrr'_ o-~ridinvloxalcarhon;~llaminolethox~,l~olv(oxv-1.2-~t anediJ 1T ). S12T1 11 t 7 rIL-1 alpha was pegylated with the reagent described in Example 11, alpha-methyl-omega-[2-([(2-pyridinyloxy)-,10 carbonyl]amino]ethoxy]poly(oxy-1,2-ethanediyl) SRU 111.7, according to the procedure set forth in Examples 4 and 7. Two pegylated rIL-1 alpha proteins with apparent molecular weights of 28 kD and 38 kD
were purified and accounted for SO and 25 per cent of the total proteins from the reaction mixture at 60 minutes respectively.
is l~~a_~~~ ion of IFN-alpha eoniuøated ~~EG bvmeans of th,g reagent al~~hyl.omeg,~- ..rr~Rvridi vloxvl.
20 carbonvllaminoleihox 1~ nol, (~oxv.g ?..--ethanedivll. SRL1 111_'7 IFN-alpha was pegylated with the reagent described in Example 11, alpha-methyl-omega-[2-[((2-pyridinyloxy)carbonyl]amino]-ethoxy]poly(oxy-1,2-ethanediyl) SRU 111.7, accordiztg to the 2S procedure set forth in Example 8. Forty percent of the protein was derivatized after 60 minutes and the product had an apparent molecular weight of 26 kD.

- 51 - 2~63~~6 Premaration of IFl~1-alpha con~,j,si;~ted to p .(T by means ~ he r~~Eent alaaha-~~thv -om a-f2-ff(2-,~yridi.nvloxv~-car-bonvllaminolethoxvl~,v(oxv-1 2-ethanedi~]~ SRU llt 7 ~Iternat~ve method of ~~gjating IFN-af,~ha.
Using the procedure illustrated in Example 9, IFN-alpha was conjugated to PEG by alpha-methyl-omega-[2-[[(2-pyridinyloxy)-carbonyl)amino)ethoxy)poly(oxy-1,2-ethanediyl), SRU 111.7. The specific activity of IF1V-alpha was determined as described in Example 8. The specific activity of the starting IFN-alpha was 1.7 x 108 U/mg and the specific activity of the IF1~T-alpha conjugated to PEG by alpha-methyl-omega-[2-[[(2-pyridinyloxy)carbonyl)-amino)ethoxy)poly(oxy-1,2-ethanediyl) was 0.8 x 108 U/mg which is within 2-3 fold of the IFIeT-alpha.
~xamRg l~
Preparation of IFN-al~h~~j~gatPd to PEC b~-means s~f the reagent ainha-lVYethy~-om -g~ f2-fff2-R idinvloxvl-car on,Llaminolethox~r_l,~o~ (oxv-,]~th ne i, 11 RZ,1 22S_ Using the procedure illustrated in Example 9, II~1V-alpha was pegylated by means of the reagent described in Example 11a. The specific activity as determined by the method described in Example 8 of the IFN-alpha conjugated to PEG was 0.4 x 108 U/mg demonstrating no significant loss in bioactivity .

_ s2 _ ~a~~~86 From a solution of 1 g I~PEG molecular weight 5000 dissolved in 30 ml of dry CH2C12 was distilled 10 ml of solvent. The solution was cooled to room temperature and 132 mg (0.6 mM) of di-2-pyridyl carbonate and 4 mg of DMAP were added. The resulting solution was 1 o then stirred for 14 hours and the solvent removed under vacuum.
The residue was triturated with diethyl ether and the resulting precipitate filtered. The product was then dissolved in 7 ml of dry glyme, warmed to cause dissolution, and the resulting solution allowed to cool and stand at room, temperature for several hours. The resulting precipitate was then filtered and washed with 2x5 ml of dry glyme. The solid was then dried in a vacuum oven and under a stream of nitrogen to give 0.7 g of alpha-[(2-pyridinyloxy)-carbonyl]omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7.
Anal. Calcd for C9H11N04(CH2CH20)111.7: C, 54.57; I-I, 9.02; N, 0.28. Found: C, 54.51; H, 9.19; . N, 0.28.
1~E~
Preparation of alba-f(2-P,yridanal~oxv)carbonvllomega-l~t~thoxv, poly (Oxv-1 _2_Pttean~gdiyl) SRgJ 225 13y the procedure described in Example 18, l~IIPEG
(methoxypolyethylene glycol) molecular weight 10,000 was converted to alpha-[(2-pyridinyloxy)carbonyl]omega-methoxypoly (oxy-1,2-ethanediyl), SRU 225.
Anal. Calcd for C9H11N04(CH2CH20)225: C, 54.54; H, 9.08; N, 0.14. Found: C, 54.54; H, 9.12; N, 0.11.

- s3 - 2~~~~~6 r_ea~~nt a_luha-f(2-~ rf l.g~~ lP carbon~,~ Q
methoxvnolv oxv-1 z-et n d' 1'~, SR7 IL-lra was pegylated with alpha-[(2-pyridinyloxy)carbonyl]-omega-methoxypoly (oxy-1,2-ethanediyl), SRU 111.7 by the procedure previously described in Examples 6 and 12. The l0 predominant pegylated products had apparent molecular weights of 26 kD and 33 kD and accounted for approximately 31 and 57 per cent of the total protein from the 60 minute reaction mixture, respectively.
The ability of the purified IL-lra proteins from the reaction mixture to inhibit IL-1 binding was determined as described in Example 6 and summarized in Table XIV. The 26kD pegylated IL-lra conjugate retained its binding capacity within 4-fold of IL-lra. The 33kD
conjugate lost significant binding activity as indicated by a 15-fold decrease in competitive binding activity.
TABLE XIV Inhibition of [l2slln-l 1 ,Binding b~IL-lra Proteins PegYlat~d with therea ent de~ribed in Example 18 ARparent Molecular Weight of IL-lra Protein lkD) X50 n ml 19 (unmodified) 2.0 26 8.0 33 30.0 -s4-~~~~ 1 r f reagent alpha-fl2-P;~,r,idinyloxwlcarbon~~lQ°
xnethoxvnolv loxv-1 _2°eth~npd~vl) SRU 225 IL-ra was pegylated with alpha-[(2-pyridinyloxy)-carbonyl]omega-methoxypoly (oxy-1,2-ethanediyl), SItU 225, according to the procedure set forth in Example 19. The predominant 1 o pegylated products from the 60 minute reaction method mixture had apparent molecular weights of 33 kD and 48 kD and accounted for approximately 47 and 2S per cent of the total protein from the reaction mixture, respectively.
The ability of the purified IL-lra proteins from the reaction mixture to inhibit IL-1 binding was determined as described in Examples 6 and 12 and summarized in Table XV. The 33kD protein retained activity within 6-fold of IL-lra. The higher molecular weight conjugate lost significant activity.
TABLE XV. I_nhibition of [125I1IL-1 Bin_dling, by IL-lra Proteins Pe~~lated with the reagent described in Example 18a Apparent Molecular Weight of IL-lra Protein (kD~ DSO n ml 19 (unmodified) 1.5 33 9.0 48 40.0 The pharmacokinetic profile of PEG-IL-lra was determined as described in Example 6A. The data are summarized in Table Ds. The PEG-IL-lra was delectable in the serum samples for a prolonged time compared to the unmodified IL-lra demonstrating a prolonged serum half-life. The pharmacodynamic profile of PEG-IL-lra was determined - 2~~~~~6 as described in Example 6, except that 0.05 ug of rIL,-1 alpha was administered. The data are summarized in Table D6. The response to IL-1 alone was 9203 units/ml IL-6. A prolonged inhibitory effect, compared to unmodified IL-lra, can be seen at up .to 72 hours following administration of the PEG-IL-lra demonstrating improved pharmacodynamic properties. Collectively, these data illustrate that even if a pegylated protein has diminished activity in vitro, it could have improved pharmaco-dynamic properties in vivo.
l0 _T_A,>3LE DS Pharmacokinetic Profile of IL-lra Conjugated with the reagent described in Example 18a Serum IL-lra (mg ml) Time (hr.) After Administration 1 kD 3 kD
1 . 580 6 g TABLE I~6. Pharmacodynamic Profile of IL-lra Conjugated with the rea~,ent described in Example 18 'Time hr.l Prior to IL-6 I,Unitslm~
IL-1 Administration 19 kD 26 kD

Preparation mf IlFfi1-alpha conj~atpd to PF(~ by mean~,g~,~
reagent a, hp a-f(2-1P rv idinvloxv,~ r~ bonvll,~a-tnethoxvnolv (ox, -1, . t n di 1v ). ,J~It~1 1'i1 7 The reagent alpha-[(2-pyridinyloxy)carbonyl]ornega-2o methoxypoly (oxy-1,2-ethanediyl), ~RU 111.7, was added to 1 mg of purified IFIV-alpha in 200 u1 of buffer (0.1 sodium borate, pH 9.0) in a molar ratio of 10 moles of reagent per mole IFN-alpha. The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes. Purified PEG-modified z5 IFN-alpha was then obtained according to the procedure set forth in Example 8. Thirty-six percent of the protein was derivatized and the product had an apparent molecular weight of 28 kD.
The specific activity of the purified IFN proteins from the 30 reaction mixture were determined as described in Example 8 and the values are summarized in Table XVI. The modified I>~N had a 5-6 fold decrease in biological activity in vitro.

2~~3~86 _s7_ TABLE XVI. Bioactivitv of IFN-aloha C-'onju~ated with the reagent described in Exam In a 18 Apparent Molecular lei hg t of Specific A~tivitv IhIV-alpha Protein fkDl nit m (unmodified) I.88 x 108 28 8.0 x 10~
15 The reagent alpha-[(2-pyridinyloxy)carbonyl]omega-methoxypoly (oxy-1,2-ethanediyl),, SItU 111.7, previously described in Example 18, was added to i mg of rIL-2 in 200 u1 of buffer (0.I
sodium borate, p~I 9.0) in a molar ratio of 5 moles of the reagent per one mole of rIL-2. The solutions were thoroughly mixed and the pegylation reaction was allowed to procE;ed at room ~ temperature for 60 minutes.
The predominant molecular weight species from the 60 minute reaction mixture were identified by SDS-PAGE with apparent molecular weights of 15 kD (unmodified) and 25 kD. The 25 kD
pegylated protein accounted for 60% of the total protein.

2~~3~86 _~s_ h reagent al~i~ha-_ ~(2-~, ridiny~v)carhono711otneQa.
n»~hoxvnczl~v-12-Qø~anPdivll SRL1 1117 IFN-alpha was pegylated with the reagent described in Example 18 according to the procedure described in Example 9.
The specific activity as determined by methods described in Example 8, of the starting unmodified IFN-alpha was 1.0 x 108 U/mg and the specific activity of the IFN-alpha conjugated to PEG was 0.4 x 108 U/mg demonstrating no significant loss in bioactivity.
Exam In a 22 PEG was conjugated to IFN-alpha using the reagent described in Example 18a with the procedures of Example 9. The specific activity as determined by methods described in Example 8 of the IFN-alpha conjugated to PEG was 0.3 x 108 Ulmg.
2s Exaannle 2:~
To 2 g of alpha-(2-aminoethyl)-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7 in 100 ml CII2C12 was added 94.2 mg of di-2-pyridylthionocarbonate. The solution was allowed to stir 18 hours and then extracted with a small amount of cold water. Most of the ~~~3886 CH2C12 was removed under reduced pressure and ether added to cause precipitation. The product was filtered and dried under high vacuum to give alpha-[2-(isothiocyanato)ethyl]-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7.
Anal. Calcd for C4H7N~S (CH2CH20)111.7~ C~ 53.88; H, 9.07; N, 0.28; S, 0.64. Found: C, 54.45; H, 8.93; N, 0.28; S, 0.53.
reauent alpha-f2-lTs~øt,;~.~.nanato)eth~~,~g~,-methox~nolv (oxv-1.2-ethaned,jwll SRI1111.'7 The reagent alpha-[2-(isothiocyanato)ethyl]-omega-methoxypoly (oxy-1,2-ethanediyl), SRU 111.7, previously described in Example 23 was added to I mg of purified IFN-alpha in 200 u1 of buffer (0.1 M
sodium borate, pH 9.0) in a molar ratio of 10 moles of reagent per one mole IFN-alpha. The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes. Thirty percent of the product was derivatized and had an apparent molecular weight of 26 kD.
~xamr~le 2,~
reagent a1_nha-t2-(tcothioc~anatol tt,vll Q;ne~a-methoxvuolv (oxv-1.2-ethanedivll SItL1 The reagent alpha-[2-(isothiocyanato)ethyl]-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 111.7, previously described in Example 23, was added to 1.0 mg of recombinant IL-2 (rIL-2) in 100 u1 of buffer (0.1 Ivi sodium borate, pH 9.0) in a molar ratio of 10 moles of reagent PEG per mole rIL-2. The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperatures for 20~3~~b 60 minutes. Purified PEG-modified rIL-2 was then obtained according to the procedure as set forth in Example 3. The derivatization results are summarized in Table XVII.
TABLE XVII. Modification of rIL-2 with the reagent described in Example 23 Apparent Molecular Weight of % of Total Protein rIL-2 Protein ~,kD,) from Reaction 15 (unmodified) 70 2o IL-lra was pegylated with alpha-[2-(isothiocyanato)ethyl]-omega-methoxypoly (oxy-1,2-ethanediyl), SRU 111.7, according to the procedure described in Example 6. The predominant pegylated products had molecular weights of 26, 31, 38 and 48 kD and accounted for approximately 17, 44, 15 and 10 per cent of the total protein, respectively.
The ability of the purified 26 kD IL-lra protein from the 60 minute reaction mixture to inhibit IL-1 binding was determined by methods described in Example 6 and summarized in Table XVIII. The pegylated protein retained its binding capacity within 2-3 fold of IL-lra.

- ~~~3~~6 TABLE XVIII. Inhibition of [125I1IL-1 Binding_ by IL-lra Protein Pe~vlated with the rea eg n~ t described in Example 23 Apparent Molecular VJei _h~ t of I_L-lra Protein fkD) I~0 n ml 19 2.0 26 ~.0 ~ 5 Recombinant IL-1 alpha was pegylated with alpha-[2-(isothiocyanato)ethyl]-omega-methoxypoly (oxy-1,2-ethanediyl), SRU
111.7, as described in Example 4. Two predominant molecular weight pegylated species from the 60 minute reaction mixture were identified by SDS-PAGE with apparent molecular weights of 26 and z0 38 kD. The latter two pegylated proteins accounted for 46 and 48 per cent of the total protein, respectively. The pegylated rIL-1 alpha was purified from the reaction mixture and characterized as described in Example 4.
25 The bioactivity of the pooled purified fractions were evaluated in the D10 cell proliferation assay as described in Example 7 and results summarized in Table XIX. The samples noted as mixtures in the table contained more than one protein species that was not further purified.
The 2bkD pegylated protein had a specific activity essentially 3o indistinguishable from IL-1.

TA>3LE XIX. Eioactivity of rIL-1 alpha conjugated to PEG with the r_ea;~ent described in Example 23 Apparent lVlolecular Wei hg't of Specific Activity z~I_L-1 aloha Protein k~) ni m 17 1.1 x 108 26 1.7 x 108 26, 38 (mixture) 2.0 x 108 >38 (mixture) 6.0 x 106 Exarnnle 28 From a solution of 1 g (0.1 mmol) MPEG (methoxypolyethylene glycol molecular weight 10,000) in 30 ml of CH2C12 was distilled 10 ml of solvent. The resulting solution was cooled and 69.7 mg (0.3 mmol) of di-2-pyridyl thionocarbonate and 2 mg of DNIAP added. The mixture was then stirred under an atmosphere of argon for 18 hours.
2o The solvent was removed under vacuum and the residue redissolved in a minimum of CH2C12. Ether was then added and the resulting precipitate filtered and washed with ether. The product was then dissolved in 5 ml of warm glyme and the resulting solution allowed to stand overnight. The resulting precipitate was then filtered and washed with 2x5 ml of glyme and 5 ml of diethyl ether. The product was then dried in a vacuum oven under ,a slow stream of nitrogen to give 0.9 g of alpha-j(2-pyridinyloxy)thio-carbonyl]-omega-methoxypoly (oxy-1,2-ethanediyl) SRU 225. ' Anal. Calcd for C9H11I~103S(CH3CH2G)225.3: C~ 54.46; H, 9.04.
3 o Found: C, 54.67; H, 9.30.

~0~~~~6 Preparation of IL-lra conj~g,~~er1 tn p ~' y ~,~eanc of the ~a~nT alpha-ft2-P ridi~, lox~1 lo arb~wl -orne~a-~n~thoxy,-Col~, (oxw-1.2-etha~edj~vl) It 1 alpha-[(2-Pyridinyloxy)thiocarbonyl]-omega-methoxypoly (oxy-1,2-ethanediyl), SRU 225, prepared as described in Example 28, was added to 2.0 mg of IL-lra in 1.0 ml of buffer (0.1 M sodium borate, pH 9.0) in a molar ratio of 2 moles of the reagent per one mole of IL-lra. 'The solutions were thoroughly mixed and the pegylation reaction was allowed to proceed at room temperature for 60 minutes. PEG
modified IL-lra was then purified according to the procedure set out in Example 6.
The predominant pegylated product had an apparent molecular weight of 33 kD and accounted for approximately 17% of the total protein from the 60 minute reaction mixture. The ability of the purified IL-lra proteins from the reaction mixture to inhibit IL-1 z0 binding was determined as described in Example 6 and summarized in Table XX. The binding capacity of the 33kD protein was within 3-4 fold of the IL-lra.
'TABLE XX. Inhibition of [125I1~_1 Bindin~~ by IL-lra Proteins z5 pe~vlated with the reagent described in Example 28 Molecular Weight of IL-Ira Protein (kDl ICAO n ml 19 (unmodified) l,~
30 33 5,0 2~6388G

To a solution of 10 g (0.09 mol) of 6-methyl-2-hydroxypyridine in 250 m1 of dry CH2C12 was added 12.7 ml of triethylamine. The solution was cooled to 0°C and under an atmosphere of argon was added dropwise 4.1 ml (0.046 mol) of a solution of thiophosgene in CC14 (85%). The mixture was then allowed to stir at room 1 o temperature for 5 hr., filtered and the CH2C12 solution washed twice with 100 ml of a saturated NaHC03 solution. The organic layer was dried and the solvent removed under reduced pressure. Hexane (100 ml) was then added to the residue and the resulting mixture was allowed to digest overnight. The . resulting precipitate was filtered, washed with hexane and dried in a vacuum oven under a slow stream of nitrogen to give 5.7 g of carbonothioic acid o,o-di-(6-methyl-2-pyridinyl) ester m.p. 155-156°C.
Anal. Calcd for C13H12N202S: (:, 59.98; H, 4.65; N, 10.76; S, 12.32. Found: C, 59.65; H, 4.59; N, 10.75; S, 12.06.
' ~xatn,~,~e, 3 i~
algha-Methyl.n~nne~""fir? 1T(6-nnethvll-2=~vridin thiocarb~nvllnminolethoxel~o v(ox~-1,2-ethanert~vll S1R
z~
A solution of 1 g of alpha-methoxy-omega-(2-aminoethyl) poly(oxy-1,2-ethanediyl) SRU 225 (as prepared in Example lc) and 52.7 mg of carbonothioic acid o,o-di(6-methyl-2-pyridinyl)ester (Example 30) dissolved in 15 ml of dry CH2C12 was stirred overnight at room temperature. The solvent was removed under reduced pressure and the residue triturated with diethyl ether. The precipitate was filtered and washed with ether. The product was then dissolved in 5 ml of warm glyrne and filtered through a 0.75 micron Millipore filter. The solution was then allowed to stand at room temperature for 48 hr. and the resulting precipitate filtered. The product was then dried in a vacuum oven under an atmosphere of N2 for 18 hr. to give 0.9 g of alpha-methyl-omega-[2-[[(6-methyl-2-pyridinyloxy)thiocarbonylJamino]
ethoxyJpoly(oxy-1,2-ethanediyl) SRU 225.
Anal. Calcd for ClOH14N2~2S(CH2CH20)225: C, 54.50; H, 9.09; N, 0.27; S, 0.32. Found: C, 54.38; H, 9.20; N, 0.21; S, 0.37.
l0 Examnl~ a 32 Preparation rI -lra onjsga_ted to PE t lay means of the reagent aloha-Met~vl-omega-f2-lfl6-meth~p~.
wridinvloxvlthiocarbonyllaminolethoxvl~l_ylo,~ -v 1 2-~ 5 elhanedivl) SRL1 225 The reagent prepared as previously described in Example 31 was added to 5.0 mg of purified rIL-lra in 1.0 ml 0.1 M sodium borate, pH 9.0 in a molar ratio of 2.0 moles reagent per mole rIL-lra.
2o The solution was thoroughly mixed and the reaction mixture was allowed to proceed at room temperature for 60 minutes.
The rILlra products were evaluated using the procedure described in Example 6. Table XXI shows the percent of modification of primary molecular weight species from the reaction mixture.
Table XXI. Modification of rIL-lra with the reaeent described in Example 31 Apparent Molecular Wei hg t of % of Total Protein 3o rIL-lra Protein lkD) from Reaction 19 (unmodified) 3 0 . 0 65.0 48 5.0 * Trademark - 6~ - 20~3~~6 rIL-lra products from the reaction mixture were purified using the method described in Example 6.
Purified fractions from the reaction mixture .were assayed in an rIL-1 radioreceptor competition binding assay as described previously in Example 6. The results are shown in Table XXII. These results show that the 3S kD protein was 6-fold less active than unmodified IL-lra for inhibiting Il-1 binding while the 48 kD protein was 20-fold less active.
Table XXII Inhibition of f 12SI] IL-1 bindin~~v rIL-lra coniu ated with the reagent described in Exam 1_p a 31 Apparent lVlolecular Weight of rIL-lra Protein ~kD) I p n ml 19 (unmodified) 1. S
35 9.0 48 30.0 ~x~m leg w ' - -ff(2 m ridinvlox~r)carbons,~laminol.nthoxYl_~ol~~.~.
~~han ivll~~R I 1 R

A. Preparation of aloha-(2-Chloroeth~l-omega (2 chloroethoxv)-polv(oxy-1.2-ethanediyl) SI2U 180 From a slurry of 80 g MPEG (polyethylene glycol-molecular weight 8000) in 750 ml of toluene was distilled 200 ml of the solvent.
To the refluxing solution was added dropwise 1.7 ml of dry pyridine and 4.7 ml of thionyl chloride. After refluxing for twelve hours the reaction was allowed to stir overnight. Methylene chloride (SO ml) was then added and the resulting solution filtered through 60 g of - 67 - , basic alumina (Wolem Super 1)* The column was then eluted with 500 ml of CH2C12, the organic layers combined, and the solvent removed under reduced pressure. The residue was then dissolved in 300 ml of CH2 C 12 and ether slowly added while the solvents are removed on a steam bath. This procedure is continued until a cloudy suspension develops. The resulting mixture is then stirred at room temperature for several hours and the product then filtered to give 73 g of alpha-(2-chloroethyl)-omega-(2-chloro-ethoxy)-poly(oxy-1,2-ethanediyl) SRU 180.
Anal. Calcd for C2H4C12(CH2CH20) 1 g0: C, 54.16; H, 9.09; Cl, 0.88.
Found: C, 53.40; H, 8.81; Cl, 0.93.
B. Prevaration of alpha-(2-Azidoethvll-omega-f2-azidoethoxv)-polv_(o_xv-1.2-ethanedivly SRU 180 A mixture of 72 g of alpha-(2-chloroethyl)-omega-(2-chloroethoxy)poly(oxy-1,2-ethanediyl) SRU 180, 25 g sodium azide and 700 ml of dry DMF was stirred and heated at 125°C for 12 hours.
The solvent was then removed under high vacuum and the residue 2o dissolved in one liter of CH2C12 and filtered through CeliteThe CH2C12 was then removed on a steam bath while diethyl ether was added to cause precipitation. The mixture was stirred overnight and then filtered. The precipitate was then dissolved in a minimum of glyme at SO°C, slowly cooled and filtered. The product then dried in a vacuum oven under a stream of N2 to give 69 g of alpha-(2-azidoethyl)-omega-(2-azidoethoxy)-poly(oxy-1,2-ethanediy1) SRU 180.
A. pal. Calcd for C2H4N6(CH2CH20)1g0: C, 54.07; H, 9.08; N, 1.044. Found: C, 53.76; H, 9.28; N, 0.96.
C. Preparation of alpha-(2-Aminoethyl) omega (2 aminoethoxv)pol~oxy-12-ethanedi~) SRU 180 A solution of 69 g of alpha-(2-azidoethyl)-omega-(2-azidoethoxy)poly(oxy-1,2-ethanediyl) SRU 180 and 6.7 g (25.6 mmol) * Trademarks _ 2~6~~~6 of triphenylphosphine dissolved in 200 ml of dry CH2C12 was stirred overnight under an atmosphere of argon. Ydater (2 ml) was added and the mixture stirred an additional 12 hours. Most of methylene chloride was removed under vacuum and 400 ml of diethyl ether added. The precipitate was filtered, washed with ether and dissolved in 300 ml of warm (SO°C) glyme. The solution was allowed to stand at room temperature overnight and the resulting precipitate filtered, washed with 2x100 ml of glyme, 2x100 ml of diethyl ether and dried in a vacuum oven under a stream of N2 to give 66 g of alpha-(2-1o aminoethyl)-omega-(2-aminoethoxy)poly(oxy-1,2-ethanediyl) SRU

Anal. Calcd for C2HgN2(CH2CH20)1g0: C, 54.42; H, 9.18; N, 0.35.
Found: C, S3.8S; H, 9.20; N, 0.43.
D. aloha-f2-fff2-Pvridinyloxv)carbonvllaminolethYll omeea f2 ff(2 rid'n 1 x r mi h 1 -1 2- bane t 1 R
From a solution of 1 g of alpha-(2-aminoethyl)-omega-(2-aminoethoxy)poly(oxy-1,2-ethanediyl) SRU 180 dissolved in 40 rnl of dry CH2C12 was distilled 15 ml of solvent. The solution was cooled to 0°C and 8S mg (6.39 mmol) of di-2-pyridyl carbonate added. The mixture was then stirred at 0°C for 4 hr and the solvent removed under vacuum. The residue was triturated with diethyl ether and the product filtered and washed with ether (2x?S ml). The product was then dried under vacuum and dissolved in 8 ml of dry glyme (SO°C).
The solution was then allowed to cool and stand at room temperature far 12 hr. The precipitated product was filtered, washed with 2 x S
ml of glyme and dried in a vacuum oven under a stream of N2 to give 1 g of alpha-[2-[[(2-pyridinyloxy)carbonyl] amino]ethyl]-omega-[2-[ [(2-pyridinyloxy)carbonyl]
amino]ethoxy] poly-(oxy-1,2-ethanediyl) SRU 180.
Anal. Calcd for C14H14N4~4(CH2CH2O)1g0: C, S4.S?; H, $.99; N, 0.68. Found: C, 54.32; H, 8.?9; N, 0.7?.

206~~~~

Exaznnle 34 ~l~h_a--f 2-f 1(2-P,yridinvloxv)carbonyllamino~let~vHl-omega-f 2-Lf(2-nvridinvloxp)car~honvllmninoi-ethoxplnolp(oxp 1 2 ~tha-~ nedivl~ SRi~ 4S2 A. Preparation of alpha-(2-Chloxoeth~l)-ome~,a (2 chloroethoxvl-pol~(oxv-12-ethanedivl) SRU 45~
l0 By the procedure described in Example 33A, polyethylene glycol molecular weight 20,000 was converted to alpha-(2-chloroethyl)-omega-(2-chloroethoxy)-poly(oxy-1,2-ethanediyl) SRU
452.
Anal. Calcd for C2H4C12(CH2CH2Q)452: C, 54.38; H, 9.13; Cl, 0.35.
Found: C, 54.36; H, 9.23; Cl, 0.40.
B. Frenaration of al~h~2-Azidoethyl)-omeea-(2-azidoethoxvl-~olv(oxv-1.2-ethanediyl) SRU 452 By the procedure described in Example 338, alpha-(2-chloroethyl)-omega-(2-chloroethoxy)-poly(oxy-1,2-ethanediyl) SRU
452 was converted to alpha-(2-azidoethyl)-omega-(2-azidoethoxy)-poly-(oxy-1,2-ethanediyl) SRU 452.
Anal. Calcd for C2H4N6(CH2CH20)~~52: C, 54.35; H, 9.12; N, 0.42.
Found: C, 54.38; H, 9.30; N, 0.47.
C. Preparation of alpha-(2-Aminoethvl) omega (2 aminoethoxvl~ol~r(oxv-12-ethanedivl) SRU 452 By the procedure described in Example 33C, alpha-(2-azidoethyl)-omega-(2-azidoethoxy)-poly(oxy-1,2-ethanediy1) SRU 452 was converted to alpha-(2-aminoethyl)-omega-(2-aminoethoxy)poly(oxy-1,2-ethanediyl) SRU 452.

206~~~~

Anal. Calcd for C2HgN2(CH2CH20)452: C, 54.49; H, 9.17; N, 0.14.
Found: C, 54.44; H, 9.19; N, 0.15.
D. aloha-f2-fff2-Pyridin~y)carbonvllaminoleth~rll-omega-f2 ff~
n~rridinvloxv)car-bon~rliaminolethox~poly~oxv-12-ethanedivll SRI1 452.
Ey the procedure described in Example 33D, alpha-(2-aminoethyl)-omega-(2-aminoethoxy)poly(oxy-1,2-ethanediyl) SRLT
452 was converted to alpha-[2-[[(2-pyridinyloxy)carbonyl]amino]-ethyl]-omega-[2-[[(2-pyridinyloxy)car-bonyl]amino]ethoxy]poly(oxy-1,2-ethanediyl) SRU 452.
Anal. Calcd for C14H14N4o4(CH2CH2~)452: C~ 54.56; H, 9.08; N, 0.28. Found: C, 54.33; H, 9.13; N, 0.33.
Exa~mnle 3"~
Premarationr1L-lr~~ Co~jugate~ to PEG
,ky m eansof ~~g rea~e_n_tali~ha-f2-ff(2-,~dinyloxv~)carbonvllaminol[gthyll-ri Q~.e_~a-f2-fff2-gyri ~ vloxp)s~rhnn'~ll~mjpOlethoxvlnolv-2o foxy-12-~ethanediyl~ SRL1 Gf52 The reagent prepared as previously described in Example 34 was added to 5.0 mg of purified rIL-lra in 1.0 ml 0.1 M sodium borate, pH 9.0 in a molar ratio of 1,0 moles of reagent per 4,0 moles rIL-lra. The solution was thoroughly mixed at room temperature for 60 minutes.
The rIL-lra products were evaluated using the method previously described in Example 6. Table XXIII shows the percent of 3o modification of primaxy molecular weight species from the reaction mixture.

20638~~

Table XXIII. Modification of rIL-lra with the reagent described in Example 33 Aptoarent Molecular Weight of °!o of "Total Protein rIL-lra Protein fkl~) from Reaction 19 (unrnod~ed) 50.0 55 35.0 75 15.0 15 A solution of 4.6 g (42 mmol) of 3-methyl-2-hydroxypyridine and 6 ml of triethylamine dissolved in 20 ml of CH2C12 was added dropwise at 0°C to a solution of 50 ml of CH2Cl2 and 11 ml of phosgene in toluene (1.93 malar). The nuxture was stirred at 0°C for 2 hr. and then at room temperature of 2 hr. The reaction m.ixtuxe was 2o then washed with a saturated NaHC03 solution followed by a saturated NaCI solution and then dried (Na2S04). The solvent was removed under reduced pressure and the residue crystallized from EtOAc/hexane to give 3 g of bis-(3-methyl-2-pyridyl) carbonate m.p.
110-112°C.
25 Anal. Calcd for C13H12N2O3: C, 63.93; H, 4.95; N, 11.47. Found:
C, 63.78; H, 4.86; N, 11.23.
3o almlia-Metl~vl-o~me~a-f2»flf~-m~el 2 gwri invloxy From a solution of 1 g of alpha-methoxy-omega-(2-aminoethyl)poly(oxy-1,2-ethanediyl) SRU 225 dissolved in 25 ml of 2~~3~8~

CH2C12 was distilled 10 ml of solvent. To the solution was then added 49.2 mg (0.2 mmol) of bis-(3-methyl-2-pyridyl)carbonate and the resulting mixture stirred overnight under an atmosphere of argon.
The solvent was then removed under reduced pressure and 80 ml of diethyl ether added to the residue. The solid was filtered, washed with ether and then dissolved in 10 ml CH2C12. Ether was then slowly added while boiling off the solvent until the solution becomes turbid.
The mixture was then allowed to stand for 18 hr. at room temperature and the resulting precipitate filtered. The solid was then dissolved in 8 ml of warm glyme and allowed to sit at room temperature for an additional 18 hr. The product was then filtered and dried in a vacuum oven under an atmosphere of nitrogen to give 0.6 g of alpha-methyl-omega-[2-[[(3-methyl-2-pyridinyloxy)carbonyl]amino]ethoxy]poly(oxy-1,2-ethanediyl) SRU
225.
~. Calcd for C1pH14N203(CH2CH20)225: C, 54.59; H, 9.09; N, 0.28. Found: C, 55.64; H, 9.14; N, 0.22.
Exam In a Freuaration~rj~r,g~,~~l~~~l~~~~ by means of the r~a,g~nt~, a1_~L11 -h~l"_o_'p~e~a-i2-f('(3 .~.~ns t hr~,-nvridin,y,l xv~~r onxjlaminolethoxyl~_l, (oxv-1.2-~thane i I~~R 22~
The reagent prepared as previously described in Example 37 was added to 5.0 mg of purified rIL-lra in 1.0 ml 0.1 M sodium borate, pH 9.0 in a molar ratio of 2.0 moles reagent per mole rIL-lra.
The solution was thoroughly mixed and the reaction was allowed to proceed at room temperature fox 60 minutes.
The rIL-lra products were evaluated using the procedure described in Example 6. Table XXId shows the percent of - 73 _ ~06388~
modification of primary molecular weight species from the reaction mixture.
Table XXIV Modification of rIL-Ira with the reagent described in_ Example 37 Apparent Molecular Weight of %d of Total Protein rIL-lra Protein (".kDl from Reaction 19 (unmodified) 4 ~ , 0 35 43.0 45 12.0 rIL-lra products from the reaction mixture were purified as described in Example 6. Purified fractions from the reaction mixture were assayed in an rIL-1 radioreceptor competition binding assay as described in Example 6. The results are shown in Table XXV. The 35 kD protein was 4-fold less active than unmodified IL-lra for inhibiting IL-1 binding. The 45 kD protein was 30-fold less active.
Table XXV. Tnhibi~on,~1125I] IL~1 l,~~ding~bY rIL-lra conj.u_ ag_ ted with the red, e~ nt -,described in Exam 1~~
Apparent Molecular Wei hit of r_IL-lra Protein ,~kD) I~'S0 n ml 19 (unmodified) 1.0 4.0 30.0

Claims (26)

1. A physiologically active conjugate of a protein of the formula wherein R1 is lower alkyl; R2 is -O- or -NH-; R3 is =N-R4 =S or =O; R4 is lower alkyl or cycloalkyl wherein alkyl contains 1 to 6 carbon atoms; m and n are selected from integers >= 1 in a way that the conjugate has at least a portion of the biological activity of the non conjugated protein; and wherein the protein is interleukin-1, interleukin-1ra, interferon-alpha or interleukin-2;

with the proviso that when R2 is -O-, R3 is other than =N-R4; and that when R2 is -O- and R3 is =O the protein is not interleukin-2.
2. A protein conjugate of claim 1 wherein m and n are selected in a way that the molecular weight of the pegylation residue(s) per protein molecule is from 300 to 30,000 daltons.
3. A protein conjugate of claim 1 or claim 2 wherein m is 1 or 2.
4. A protein conjugate of any one of claims 1-3 of the formula wherein R1, R4, m, n and the protein are as in claim 1.
5. A protein conjugate of any one of claims 1-3 of the formula wherein R 1, m, n and the protein are as in claim 1.
6. A protein conjugate of any one of claims 1-3 of the formula wherein R1, m, n and the protein are as in claim 1.
7. A protein conjugate of any one of claims 1-3 of the formula wherein R1, m, n and the protein are as in claim 1.
8. A protein conjugate of any one of claims 1-3 of the formula wherein R 1, m, n and the protein are as in claim 1.
9. A protein conjugate according to any one of claims 1-8 wherein R1 is CH3,
10. The protein conjugate of claim 1 of the formula wherein n is about 112.
11. The protein conjugate of claim 1 of the formula wherein n is about 112.
12. The protein conjugate according to any one of claims 1-9 wherein the interferon-alpha is interferon-alpha A.
13. A compound selected from the group consisting of II-A R1O(CH2CH2O)n -CH2CH2-N=C=N-R4 II-D R1O(CH2CH2O)n -CH2-CH2-N=C=S
wherein R1 is lower alkyl, R4 is lower alkyl or cycloalkyl, R5 is lower alkyl or H and n is any integer of from 1 to 1000, wherein alkyl contains 1 to 6 carbon atoms.
14. A compound of claim 13 wherein R4 is cyclohexyl.
15. A compound of claim 13 wherein R5 is H.
16. A compound of claim 13 wherein R5 is CH3.
17. A compound according to any one of claims 14-16 wherein R1 is CH3.
18. A compound with the formula wherein R1 is CH3 and n is about 112.
19. Protein conjugates in accordance with any one of claims 1-12 for use as therapeutically active compounds in the treatment or prophylaxis of illnesses.
20. Process for the preparation of a protein conjugate claimed in any one of claims 1-12 wherein the protein is interleukin-1, interleukin-1ra, interferon-alpha or interleukin-2, which process comprises reacting a compound selected from the group consisting of II-A ~R1O(CH2CH2O)n -CH2CH2-N=C=N-R4 II-D ~R1O(CH2CH2O)n -CH2-CH2-N=C=S
wherein R1 is lower alkyl, R4 is lower alkyl or cycloalkyl, R5 is lower alkyl or H and n is any integer of from 1 to 1000, wherein alkyl contains 1 to 6 carbon atoms, with a free amino group of a protein of the formula wherein R1 is lower alkyl; R2 is -O- or -NH-; R3 is =N-R4, =S or =O; R4 is lower alkyl or cycloalkyl wherein alkyl contains 1 to 6 carbon atoms; m and n are selected from integers >= 1 in a way that the conjugate has at least a portion of the biological activity of the non conjugated protein; and wherein the protein is interleukin-1, interleukin-1ra, interferon-alpha or interleukin-2;

with the proviso that when R2 is -O-, R3 is other than =N-R4; and that when R2 is -O- and R3 is =O the protein is not interleukin-2, or a salt thereof, and isolating the protein conjugate from the reaction mixture.
21. Pharmaceutical compositions comprising a protein conjugate as claimed in any one of claims 1-12 together with a therapeutically acceptable carrier.
22. Pharmaceutical compositions for the treatment or prophylaxis of immunomodulatory disorders comprising a protein conjugate as claimed in any one of claims 1-12 together with a therapeutically acceptable carrier.
23. A composition as in claim 22 wherein the immunomodulatory disorder is a neoplastic disease or an infectious disease.
24. The use of the protein conjugates according to any one of claims 1-12 in the treatment or prophylaxis of immunomodulatory disorders.
25. The use of the protein conjugates according to any one of claims 1-12 for the manufacture of medicaments for use in the treatment or prophylaxis of immunomodulatory disorders.
26. A use as in claim 24 or claim 25, wherein the immunomodulatory disorder is a neoplastic disease or an infectious disease.
CA002063886A 1991-03-25 1992-03-24 Polyethylene protein conjugates Expired - Lifetime CA2063886C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67400191A 1991-03-25 1991-03-25
US674,001 1991-03-25
US07/767,000 US5595732A (en) 1991-03-25 1991-09-27 Polyethylene-protein conjugates
US767,000 1991-09-27

Publications (2)

Publication Number Publication Date
CA2063886A1 CA2063886A1 (en) 1992-09-26
CA2063886C true CA2063886C (en) 2002-08-20

Family

ID=27101069

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002063886A Expired - Lifetime CA2063886C (en) 1991-03-25 1992-03-24 Polyethylene protein conjugates

Country Status (32)

Country Link
US (7) US5595732A (en)
EP (1) EP0510356B1 (en)
JP (1) JP2637010B2 (en)
KR (1) KR920018079A (en)
CN (2) CN1038035C (en)
AT (1) ATE176159T1 (en)
AU (2) AU657311B2 (en)
BG (1) BG60800B2 (en)
BR (1) BR9201015A (en)
CA (1) CA2063886C (en)
CS (1) CS87192A3 (en)
CY (1) CY2169B1 (en)
DE (1) DE69228269T2 (en)
DK (1) DK0510356T3 (en)
EE (1) EE9400356A (en)
ES (1) ES2128329T3 (en)
FI (2) FI107927B (en)
GR (1) GR3030049T3 (en)
HU (2) HUT60512A (en)
IE (1) IE920936A1 (en)
IL (1) IL101348A0 (en)
IS (1) IS3824A (en)
MW (1) MW1892A1 (en)
MX (1) MX9201298A (en)
MY (1) MY131095A (en)
NO (1) NO921142L (en)
NZ (2) NZ242084A (en)
OA (1) OA09760A (en)
RO (1) RO109543B1 (en)
SI (1) SI9210294A (en)
ZA (1) ZA922110B (en)
ZW (1) ZW4392A1 (en)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
JPH09504033A (en) * 1993-10-20 1997-04-22 エンゾン，インコーポレーテッド 2'- and / or 7-substituted taxoids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
WO1995013090A1 (en) * 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
DE19512484A1 (en) * 1995-04-04 1996-10-17 Bayer Ag Carbohydrate modified cytostatics
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
ES2093593T1 (en) * 1995-05-05 1997-01-01 Hoffmann La Roche RECOMBINANT OBESE PROTEINS (OB).
EP0858343B1 (en) 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ATE200030T1 (en) * 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc PEGYLATION PROCEDURE
US6321909B1 (en) 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
ES2215295T3 (en) 1997-02-21 2004-10-01 Genentech, Inc. CONJUGATES OF POLYMERS AND ANTIBODY FRAGMENTS.
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
FR2774687B1 (en) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med LIPOPEPTIDES CONTAINING A FRAGMENT OF THE INTERFERON GAMMA, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
IL139286A (en) * 1998-04-28 2005-12-18 Applied Research Systems Polyol-ifn-beta conjugates, their preparation and use
CN1230198C (en) 1998-05-15 2005-12-07 先灵公司 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having G chronic hepatitis C infection
EP1087778B1 (en) * 1998-06-08 2005-10-26 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EE04967B1 (en) 1998-10-16 2008-02-15 Biogen, Incorporated Glycylated Interferon Beta, its Use and a Pharmaceutical Composition, Method for Prolonging Interferon Beta-1a Activity, and Preparing a Protein of the Invention
MXPA01003790A (en) * 1998-10-16 2002-09-18 Biogen Inc Interferon-beta fusion proteins and uses.
DE69934425T2 (en) * 1998-10-23 2007-09-27 Amgen Inc., Thousand Oaks THROMBOPOIETIN SUBSTITUTE
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
PT1043026E (en) 1999-04-08 2005-09-30 Schering Corp MELANOMA THERAPEUTICS
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
AU4934299A (en) * 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
YU32402A (en) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Interferon gamma conjugates
KR20020065517A (en) * 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 Interferon gamma conjugates
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
DK1257295T3 (en) 2000-02-11 2009-08-10 Bayer Healthcare Llc Factor VII or VIIA-like molecules
IT1317835B1 (en) * 2000-02-15 2003-07-15 San Raffaele Centro Fond MODIFIED CYTOKINES FOR USE IN CANCER THERAPY.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
WO2002019963A2 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
EP1366075B1 (en) 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
DE60223047T2 (en) 2001-08-22 2008-07-24 Bioartificial Gel Technologies Inc., Montreal PROCESS FOR PREPARING ACTIVATED POLYETHYLENE GLYCOLS
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100488351B1 (en) * 2001-12-11 2005-05-11 선바이오(주) Novel polyethylene glycol-propionaldehyde derivatives
US6916962B2 (en) * 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100888371B1 (en) 2002-01-17 2009-03-13 동아제약주식회사 Antivirus agent comprising bridged co-polymer derivatives and interferon complexes
PL213322B1 (en) 2002-01-18 2013-02-28 Biogen Idec Inc Polyalkylene polymer compounds and uses thereof
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
CN101301475B (en) 2002-06-21 2012-12-19 诺和诺德医疗保健公司 Pegylated factor vii glycoforms
CN103319554A (en) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
EP1539814A2 (en) * 2002-07-03 2005-06-15 Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited Full-length interferon gamma polypeptide variants
ES2601143T3 (en) 2002-07-19 2017-02-14 Omeros Corporation Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom.
EP1382352A1 (en) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein conjugates and the use thereof
WO2004012773A1 (en) 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7563507B2 (en) * 2002-08-16 2009-07-21 University Of Massachusetts Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
EP1667708B9 (en) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
EA013535B1 (en) * 2002-12-26 2010-06-30 Маунтин Вью Фамэсьютикэлс, Инк. Polymer conjugate of bioactive component (variants), method for producing and use thereof, pharmaceutical products on the base thereof
US20040176655A1 (en) * 2003-02-05 2004-09-09 Ayoub Paul Marie Methods of preparing branched alkyl aromatic hydrocarbons
US20050079155A1 (en) * 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
ES2726998T3 (en) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Modified fluorinated nucleoside analogs
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
SG143252A1 (en) * 2003-10-09 2008-06-27 Ambrx Inc Polymer derivatives
CA2542179A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
ES2428358T3 (en) 2003-10-17 2013-11-07 Novo Nordisk A/S Combination therapy
CN101001866A (en) * 2004-02-02 2007-07-18 Ambrx公司 Modified human interferon polypeptides and their uses
NZ586034A (en) * 2004-02-02 2011-10-28 Ambrx Inc Modified human growth hormone polypeptides and their uses
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
JP2008507298A (en) 2004-05-19 2008-03-13 マキシジェン， インコーポレイテッド Interferon alpha polypeptides and conjugates
US20060194726A1 (en) * 2004-05-25 2006-08-31 Rueger David C Methods of treating cartilage defects
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
JP2008505119A (en) 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション Macromolecule-Factor IX Conjugate
MX2007000216A (en) * 2004-07-08 2007-03-15 Amgen Inc Therapeutic peptides.
RU2393168C2 (en) 2004-07-19 2010-06-27 Биокон Лимитед Insulin-oligomer conjugates, preparations and use thereof
BRPI0512396A (en) * 2004-07-21 2008-03-11 Ambrx Inc biosynthetic polypeptides using non-naturally encoded amino acids
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
CN101039660B (en) * 2004-08-12 2010-10-06 先灵公司 Stable pegylated interferon formulation
NZ554442A (en) * 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP2008525032A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Methods for expressing and purifying recombinant human growth hormone
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
CA2594557C (en) * 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
KR101224781B1 (en) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 Formulations of human growth hormone comprising a non-naturally encoded amino acid
PT1835938E (en) * 2004-12-27 2013-11-06 Baxter Int Polymer-von willebrand factor-conjugates
CA2596232A1 (en) 2005-01-31 2006-08-03 Effector Cell Institute The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment
MX2007014524A (en) 2005-05-18 2008-02-07 Maxygen Inc Evolved interferon-alpha polypeptides.
US20070015701A1 (en) * 2005-06-01 2007-01-18 Samuel Zalipsky Macromolecular conjugates of bone morphogenetic protein-7
JP2008541769A (en) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド Improved human interferon molecules and their use
JP2008546708A (en) 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Use of sanglifehrin in HCV
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101500606B (en) * 2005-06-24 2013-12-04 杜克大学 A direct drug delivery system based on thermally responsive biopolymers
JP4829969B2 (en) 2005-08-18 2011-12-07 アンブルックス，インコーポレイテッド tRNA compositions and uses thereof
US20070123646A1 (en) * 2005-09-13 2007-05-31 Lele Bhalchandra S Protein-polymer conjugates and synthesis thereof
EP1776963A1 (en) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
WO2007056448A2 (en) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CN101454461A (en) 2005-11-16 2009-06-10 Ambrx公司 Methods and compositions comprising non-natural amino acids
JP2009519942A (en) * 2005-12-14 2009-05-21 アンブルックス，インコーポレイテッド Compositions comprising unnatural amino acids and polypeptides, methods relating thereto, and uses thereof
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2779992T3 (en) 2005-12-20 2020-08-21 Univ Duke Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP5046030B2 (en) 2006-01-12 2012-10-10 北里第一三共ワクチン株式会社 Oral composition containing interferon alpha
US20070179094A1 (en) 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
EP1818392B1 (en) * 2006-02-14 2010-08-25 Genetix Limited Cell culture medium
EP2010222A1 (en) * 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
MX2008013119A (en) 2006-04-11 2008-10-21 Novartis Ag Hcv/hiv inhibitors an their uses.
JO3324B1 (en) 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
RU2008145084A (en) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO
EP1897557A1 (en) * 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
MX2009002526A (en) * 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
DK2061878T3 (en) * 2006-09-08 2014-04-07 Ambrx Inc HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
JP5840345B2 (en) * 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof
KR101476472B1 (en) * 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 Modified fgf-21 polypeptides and their uses
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
NZ580686A (en) * 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
MX2010003979A (en) 2007-10-16 2010-06-02 Biocon Ltd An orally administerable solid pharmaceutical composition and a process thereof.
AU2008326324B9 (en) 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
AR071478A1 (en) 2008-04-17 2010-06-23 Baxter Healthcare Sa PEPTIDES OF LOW MOLECULAR WEIGHT WITH PROCOAGULANT ACTIVITY FOR THE TREATMENT OF PATIENTS WITH FACTOR DEFICIENCY V (FV), FVII, FVIII, FX AND / OR FXI
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
JP2011526303A (en) 2008-06-27 2011-10-06 デューク ユニバーシティ A therapeutic agent containing an elastin-like peptide
ES2963062T3 (en) 2008-07-23 2024-03-25 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
CN101671390B (en) * 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 Human interferon alpha derivatives and preparation and use of pegylated products thereof
BRPI0919403A2 (en) 2008-09-26 2017-09-26 Ambrx Inc modified animal erythropoietin polypeptides and their uses
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
CN102325783A (en) 2008-12-23 2012-01-18 法莫赛特股份有限公司 Synthesis of purine nucleosides
PA8855601A1 (en) 2008-12-23 2010-07-27 NUCLEOSID FORFORMIDATES
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CN101870728A (en) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 Novel Exendin variant and conjugate thereof
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (en) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
ES2602629T3 (en) * 2009-06-04 2017-02-21 The University Of North Carolina At Chapel Hill Compounds and methods to treat bone disorders and control weight
US20110097302A1 (en) * 2009-07-16 2011-04-28 Ta Tung Yuan Il-1ra-polymer conjugates
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
RU2589255C2 (en) * 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Modified vasoactive intestinal peptides
US8475652B2 (en) 2009-10-19 2013-07-02 Jan A. K. Paul Method for purification of uncatalyzed natural fuels from metal ions by means of at least one hemeprotein and use of the at least on hemeprotein
BR112012010110A2 (en) 2009-10-30 2019-09-24 Boehringer Ingelheim Int hcv combination therapy dosage regimens comprising bi201335, interferon alfa and ribavirin
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
JP2013528374A (en) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Polypeptide inhibitors of VLA4
JP2013529627A (en) 2010-06-24 2013-07-22 パンメド リミテッド Treatment of hepatitis C virus-related disease using hydroxychloroquine or a combination of hydroxychloroquine and an antiviral agent
EP2605789B1 (en) 2010-08-17 2019-06-05 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CN103415619B (en) 2010-09-03 2015-10-14 中央研究院 Anti-C-MET antibody and using method thereof
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
CA2811700A1 (en) 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
EA037083B1 (en) 2010-11-12 2021-02-03 Нектар Терапьютикс Immunomodulating conjugate comprising il-2 and water-soluble polymers
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
CN103221053A (en) 2010-11-30 2013-07-24 诺华有限公司 New treatments of hepatitis c virus infection
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
KR20140007927A (en) 2011-03-31 2014-01-20 노파르티스 아게 Alisporivir to treat hepatitis c virus infection
PL2694087T3 (en) 2011-04-01 2015-06-30 Novartis Ag Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2760461A1 (en) 2011-09-27 2014-08-06 Novartis AG Alisporivr for treatment of hepatis c virus infection
US8767214B2 (en) 2011-10-06 2014-07-01 Nordson Corporation Powder flow detection
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013161895A1 (en) * 2012-04-25 2013-10-31 第一三共株式会社 Bone repair promoter
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
KR102165464B1 (en) 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Antibody specific for cd22 and methods of use thereof
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
SI3584255T1 (en) 2012-08-31 2022-05-31 Sutro Biopharma, Inc Modified amino acids comprising an azido group
CN104870475B (en) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 Anticomplement C1s antibody and its purposes
LT2914291T (en) 2012-11-02 2022-06-10 Bioverativ Usa Inc. Anti-complement c1s antibodies and uses thereof
US10550171B2 (en) 2012-11-21 2020-02-04 The Governors Of The University Of Alberta Immunomodulatory peptides and methods of use thereof
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
CN105339002B (en) 2013-06-10 2019-06-28 伊皮埃里安股份有限公司 The method for treating tau lesion
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
PL3038601T3 (en) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
CN111569063A (en) 2013-11-27 2020-08-25 伊皮埃里安股份有限公司 Methods of treating tauopathy
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
ES2824028T3 (en) 2014-08-19 2021-05-11 Biogen Ma Inc PEGylation method
KR20240024362A (en) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 Modified fgf-21 polypeptides and uses thereof
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
JP7074341B2 (en) 2015-09-02 2022-05-24 イムテップ エス．アー．エス． Anti-LAG-3 antibody
KR102181168B1 (en) 2015-11-03 2020-11-23 에프. 호프만-라 로슈 아게 Combination treatment of HBV capsid assembly inhibitor and interferon
CR20180529A (en) 2016-04-04 2019-03-21 Bioverativ Usa Inc ANTI-FACTOR ANTIBODIES BB OF THE COMPLEMENT AND USES OF THESE CROSSED REFERENCES
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
MX2019008449A (en) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof.
SG11202000167SA (en) 2017-07-11 2020-02-27 Synthorx Inc Incorporation of unnatural nucleotides and methods thereof
CA3071016A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. Cytokine conjugates for the treatment of autoimmune diseases
SG11202102427XA (en) 2018-09-11 2021-04-29 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
EP3867265A1 (en) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
MA54952A (en) 2019-02-06 2022-05-11 Synthorx Inc IL-2 CONJUGATES AND METHODS OF USING THE SAME
JP2022520792A (en) 2019-02-12 2022-04-01 アンブルックス，インコーポレイテッド Compositions, Methods, and Uses Containing Antibody-TLR Agonist Conjugates
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of use thereof
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (en) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (en) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (en) * 1968-07-16
BE758425A (en) * 1969-12-02 1971-04-16 Baxter Laboratories Inc STREPTOKINASE CHEMICALLY LINKED TO A CARBOHYDRATE MATRIX (
DE2247163A1 (en) * 1972-09-26 1974-03-28 Merck Patent Gmbh CARRIER MATRIX FOR FIXING BIOLOGICALLY ACTIVE SUBSTANCES AND THE PROCESS FOR THEIR PRODUCTION
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
US4275000A (en) * 1977-08-22 1981-06-23 National Research Development Corporation Peptide macromolecular complexes
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (en) * 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896785A (en) * 1981-12-04 1983-06-08 Stanley Electric Co Ltd Formation of synthetic resin lens for light-emitting diode
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (en) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Purification of lpf-ha
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (en) * 1985-06-26 1991-02-07 Cetus Corp SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION.
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US5034514A (en) * 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
JPH0443882Y2 (en) * 1986-06-23 1992-10-16
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
AU611932B2 (en) * 1987-08-21 1991-06-27 Wellcome Foundation Limited, The Novel complex
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4660789A (en) * 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE300519T1 (en) * 1989-04-19 2005-08-15 Enzon Inc METHOD FOR PRODUCING MODIFIED POLYPEPTIDES CONTAINING A POLYPEPTIDE AND A POLYALKYLENE OXIDE
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
WO1991008229A1 (en) * 1989-12-01 1991-06-13 Basf Aktiengesellschaft Hirudine polyalkylene glycol conjugates
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates

Also Published As

Publication number Publication date
KR920018079A (en) 1992-10-21
RO109543B1 (en) 1995-03-30
IL101348A0 (en) 1992-11-15
AU657311B2 (en) 1995-03-09
GR3030049T3 (en) 1999-07-30
ZA922110B (en) 1992-11-25
HU9200955D0 (en) 1992-05-28
EP0510356A1 (en) 1992-10-28
HUT60512A (en) 1992-09-28
MW1892A1 (en) 1994-01-12
EP0510356B1 (en) 1999-01-27
MX9201298A (en) 1992-10-01
AU1316092A (en) 1992-10-01
US5849860A (en) 1998-12-15
US5559213A (en) 1996-09-24
IE920936A1 (en) 1992-10-07
CN1108814C (en) 2003-05-21
ZW4392A1 (en) 1992-09-23
BR9201015A (en) 1992-11-24
JP2637010B2 (en) 1997-08-06
CA2063886A1 (en) 1992-09-26
FI20011554A (en) 2001-07-17
US5539063A (en) 1996-07-23
FI921267A (en) 1992-09-26
CN1175465A (en) 1998-03-11
BG60800B2 (en) 1996-03-29
MY131095A (en) 2007-07-31
DE69228269T2 (en) 1999-07-08
DK0510356T3 (en) 1999-09-13
ATE176159T1 (en) 1999-02-15
ES2128329T3 (en) 1999-05-16
IS3824A (en) 1992-09-26
EE9400356A (en) 1996-04-15
HU211945A9 (en) 1996-01-29
CS87192A3 (en) 1992-10-14
US5792834A (en) 1998-08-11
FI921267A0 (en) 1992-03-24
US5834594A (en) 1998-11-10
OA09760A (en) 1993-11-30
SI9210294A (en) 1995-10-31
NO921142D0 (en) 1992-03-24
JPH05117300A (en) 1993-05-14
AU671045B2 (en) 1996-08-08
US5747646A (en) 1998-05-05
AU7761594A (en) 1995-01-12
CY2169B1 (en) 2002-08-23
NZ248022A (en) 1993-12-23
US5595732A (en) 1997-01-21
CN1065465A (en) 1992-10-21
DE69228269D1 (en) 1999-03-11
CN1038035C (en) 1998-04-15
FI107927B (en) 2001-10-31
NZ242084A (en) 1993-12-23
NO921142L (en) 1992-09-28

Similar Documents

Publication Publication Date Title
CA2063886C (en) Polyethylene protein conjugates
JP2859105B2 (en) Interferon conjugate
JP2980569B2 (en) Interferon complex
CZ20003995A3 (en) Polyol and interferon-beta conjugate
US5010176A (en) Antibody-drug conjugates
JP2005514505A (en) Preparation and use of multi-arm dendritic and functional PEG
US20030103934A1 (en) Drugs having long-term retention in target tissue
KR100480432B1 (en) Conjugates of granulocyte-colony stimulating factor and polyethylene glycol derivatives
KR100888371B1 (en) Antivirus agent comprising bridged co-polymer derivatives and interferon complexes
KR100761652B1 (en) multi-branched polymer used in conjugating protein or peptide, and resulting conjugator

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry